name: OCTISALATE 4.5 g in 100 mL / OCTOCRYLENE 4.5 g in 100 mL / AVOBENZONE 1.8 g in 100 mL TOPICAL CREAM [Bioresist reinforcing effect face moisturizer SPF 30]


name: ZINC OXIDE 224 mg in 1 g TOPICAL CREAM [Self Reflect Probiotic Sunscreen Moisturizer Broad Spectrum SPF 32]


name: ZINC OXIDE 99 mg in 1 mL / OCTOCRYLENE 80 mg in 1 mL / OCTINOXATE 75 mg in 1 mL / OCTISALATE 50 mg in 1 mL TOPICAL LOTION [Sheer Broad Spectrum SPF45]


name: Niacinamide 3.0 g in 150 mL / Adenosine 0.06 g in 150 mL TOPICAL LIQUID [BLUE TOK TOK TOK ALL IN ONE CAPSULE ESSENCE]


name: AVOBENZONE 1.278 g in 50 mL / OCTINOXATE 3.785 g in 50 mL / OCTOCRYLENE 1.534 g in 50 mL / HOMOSALATE 2.557 g in 50 mL TOPICAL CREAM [SHISEIDO VITAL PERFECTION UPLIFTING AND FIRMING DAY]


name: OCTISALATE 2.523 g in 50 mL / OCTOCRYLENE 3.532 g in 50 mL / ZINC OXIDE 7.723 g in 50 mL TOPICAL CREAM [SHISEIDO FUTURE solution LX UNIVERSAL DEFENSE E]


name: OCTISALATE 3.105 g in 50 mL / TITANIUM DIOXIDE 2.359 g in 50 mL / OCTOCRYLENE 4.347 g in 50 mL / ZINC OXIDE 12.047 g in 50 mL TOPICAL CREAM [SHISEIDO ULTIMATE SUN PROTECTOR]


name: CHLOROXYLENOL 0.3 g in 100 mL TOPICAL SOAP [Radiance Antibacterial Citrus Scent Hand]


name: CHLOROXYLENOL 0.3 g in 100 mL TOPICAL SOAP [Radiance Antibacterial Green Apple Scent Hand]


name: Leflunomide 1 g in 1 g NOT APPLICABLE POWDER


name: AVOBENZONE 3 g in 100 g / OCTISALATE 5 g in 100 g / OCTOCRYLENE 10 g in 100 g TOPICAL STICK [Glow Stick Broad Spectrum SPF 50]


name: ZINC OXIDE 10 g in 100 g TOPICAL GEL [SKINSUIT LIP SPF 30]


name: NIACINAMIDE 3 g in 100 mL / ADENOSINE 0.04 g in 100 mL TOPICAL LIQUID [RETURN10 DERMA CELL REPAIR AMPOULE]


name: ADENOSINE 0.04 g in 100 mL TOPICAL LIQUID [RETURN 10 MTSSOLUTION]


name: ZINC OXIDE 12 g in 100 mL TOPICAL LOTION [SKINSUIT FACE SPF 50]


name: Niacinamide 0.4 g in 20 mL / Adenosine 0.008 g in 20 mL TOPICAL PATCH [JEJU LAVA SEA WATER ALL DAY BRIGHTENING MASK]


name: Niacinamide 1.0 g in 50 mL / Adenosine 0.02 g in 50 mL TOPICAL CREAM [SKINMD LABRATORIES DAY AND NIGHT BRIGHTENING]


name: Oxaceprol 1 g in 1 g NOT APPLICABLE POWDER


name: CALCIUM DOBESILATE 1 g in 1 g NOT APPLICABLE POWDER


name: PENICILLAMINE 1 kg in 1 kg NOT APPLICABLE POWDER


name: ALUMINUM CHLOROHYDRATE 23.3 g in 100 g TOPICAL AEROSOL, SPRAY [Antiperspirant Dry 1.6 oz Men Antiperspirant]


name: LEVETIRACETAM 1 kg in 1 kg NOT APPLICABLE POWDER


name: MIRTAZAPINE 1 g in 1 g NOT APPLICABLE POWDER


name: ALUMINUM CHLOROHYDRATE 23.3 g in 100 g TOPICAL AEROSOL, SPRAY [Antiperspirant Dry 1.6 oz Lady Antiperspirant]


name: SALICYLIC ACID 30 mg in 6 g TOPICAL POWDER [bareMinerals Blemish Rescue Skin-Clearing Loose Foundation Deepest Deep 6C]


name: {1 (0.1 ML) (diazepam 50 MG/ML Nasal Spray [Valtoco]) } Pack [Valtoco 5 MG Dose Kit]


name: {2 (0.1 ML) (diazepam 75 MG/ML Nasal Spray [Valtoco]) } Pack [Valtoco 15 MG Dose Kit]


name: Ampicillin Trihydrate 1 kg in 1 kg NOT APPLICABLE POWDER


name: COSYNTROPIN 1 g in 1 g NOT APPLICABLE POWDER


name: Octinoxate 3.50 g in 50 mL / Titanium Dioxide 4.41 g in 50 mL / Zinc Oxide 2.00 g in 50 mL TOPICAL CREAM [MIZON SNAIL REPAIR INTENSIVE BB 21]


name: ALUMINUM ZIRCONIUM TETRACHLOROHYDREX GLY 159 mg in 1 g TOPICAL STICK [Lady Speed Stick Power Wild Freesia]


name: OCTISALATE 27.5 g in 1000 g / OCTINOXATE 75.0 g in 1000 g / ZINC OXIDE 80.0 g in 1000 g TOPICAL LOTION [Private Label Super Light Oil-Free SPF45]


name: ZINC OXIDE 80 g in 1000 g / OCTINOXATE 75 g in 1000 g / OCTISALATE 30 g in 1000 g TOPICAL LOTION [Private Label SPF45 Water Resistant Paraben Free Sunscreen]


name: AVOBENZONE 30 mg in 1 g / OCTISALATE 50 mg in 1 g / HOMOSALATE 100 mg in 1 g / OCTOCRYLENE 50 mg in 1 g TOPICAL SPRAY [Equate Sunscreen KIDS SPF50 Broad Spectrum]


name: AVOBENZONE 30 mg in 1 mL / HOMOSALATE 150 mg in 1 mL / OCTISALATE 50 mg in 1 mL / OCTOCRYLENE 100 mg in 1 mL / OXYBENZONE 60 mg in 1 mL TOPICAL LOTION [Equate Sunscreen SPORT SPF 100]


name: pen needle, diabetic, remover and disposal unit 32 gauge X 1/4" MISCELL NEEDLE, DISPOSABLE


name: nystatin 1 million unit MISCELL POWDER (EA)


name: methylcellulose 400cps 30 % MISCELL POWDER (GRAM)


name: cardioplegic solution no.31 (maintenance 4:1)


name: {1 (0.1 ML) (diazepam 100 MG/ML Nasal Spray) } Pack


name: {2 (0.1 ML) (diazepam 100 MG/ML Nasal Spray) } Pack


name: {1 (0.1 ML) (diazepam 50 MG/ML Nasal Spray) } Pack


name: {2 (0.1 ML) (diazepam 75 MG/ML Nasal Spray) } Pack


name: CATHERIZATION SET,INTERMITTENT,CLOSED 12FR MTG #32212


name: CATHETER,HYDROPHILIC 18FR FEMALE PECO #PH218F


name: CENTRAL LINE DRESSING CHANGE KIT, BARD #APDCSSB


name: CONNECTOR,ELBOW SWIVEL W/SUCTION PORT SMITHS #661991


name: DRESSING,AQUACEL FOAM 9.5IN X 8.5IN #420828


name: DRESSING,CUTIMED SILTEC BORDER 5IN X 5IN #7328401


name: INSULIN SYRINGE 1ML 28G 12MM DOUBLE SCALE


name: INSULIN SYRINGE 1ML 29G 12MM SAFETYGLIDE


name: IRRIGATION KIT W/ENFIT PISTON SYRINGE COVIDIEN#8884700108


name: SET,INFUSION,EXTENSION SMALL BORE ICU#B33024


name: SUCTION TUBE ATTACHMENT DEVICE COVIDIEN #61501023


name: TRACH STOMA PROTECTOR,BUCHANAN LUMINAUD #38008


name: TRACH VALVE HOUSING,ADHESIVE BLOM-SINGER BE6082


name: VAD DRIVELINE MAINTENANCE KIT CENTURION #DM710


name: thigh/weight bearing-gluteal/ischial weight bearing orthotic addition


name: Supplies for maintenance of insulin infusion pump with dosage rate adjustment using therapeutic continuous glucose sensing, per week


name: Parenteral nutrition solution, not otherwise specified, 10 grams lipids


name: Orthopedic/device/drug matrix for opposing bone-to-bone or soft tissue-to bone (implantable)


name: Generator, cardiac contractility modulation (implantable)


name: Catheter, pressure-generating, (e.g., one-way valve, intermittently occlusive)


name: Probe, image-guided, robotic, waterjet ablation


name: Intraoperative near-infrared fluorescence lymphatic mapping of lymph node(s) (sentinel or tumor draining) with administration of indocyanine green (icg) (list separately in addition to code for primary procedure)


name: Laminotomy (hemilaminectomy), with decompression of nerve root(s), including partial facetectomy, foraminotomy and excision of herniated intervertebral disc, and repair of annular defect with implantation of bone anchored annular closure device, including annular defect measurement, alignment and sizing assessment, and image guidance; 1 interspace, lumbar


name: Blinded procedure for nyha class iii/iv heart failure; transcatheter implantation of interatrial shunt or placebo control, including right heart catheterization, trans-esophageal echocardiography (tee)/intracardiac echocardiography (ice), and all imaging with or without guidance (e.g., ultrasound, fluoroscopy), performed in an approved investigational device exemption (ide) study


name: Implant supported retainer for metal fpd - titanium and titanum alloys


name: External ambulatory infusion pump, insulin, dosage rate adjustment using therapeutic continuous glucose sensing


name: Wheelchair accessory, dynamic positioning hardware for back


name: Brief (20 minutes) in-home visit for a new patient post-discharge. for use only in a medicare-approved cmmi model. (services must be furnished within a beneficiary's home, domiciliary, rest home, assisted living and/or nursing facility within 90 days following discharge from an inpatient facility and no more than 9 times.)


name: Limited (30 minutes) in-home visit for a new patient post-discharge. for use only in a medicare-approved cmmi model. (services must be furnished within a beneficiary's home, domiciliary, rest home, assisted living and/or nursing facility within 90 days following discharge from an inpatient facility and no more than 9 times.)


name: Moderate (45 minutes) in-home visit for a new patient post-discharge. for use only in a medicare-approved cmmi model. (services must be furnished within a beneficiary's home, domiciliary, rest home, assisted living and/or nursing facility within 90 days following discharge from an inpatient facility and no more than 9 times.)


name: Comprehensive (60 minutes) in-home visit for a new patient post-discharge. for use only in a medicare-approved cmmi model. (services must be furnished within a beneficiary's home, domiciliary, rest home, assisted living and/or nursing facility within 90 days following discharge from an inpatient facility and no more than 9 times.)


name: Extensive (75 minutes) in-home visit for a new patient post-discharge. for use only in a medicare-approved cmmi model. (services must be furnished within a beneficiary's home, domiciliary, rest home, assisted living and/or nursing facility within 90 days following discharge from an inpatient facility and no more than 9 times.)


name: Brief (20 minutes) in-home visit for an existing patient post-discharge. for use only in a medicare-approved cmmi model. (services must be furnished within a beneficiary's home, domiciliary, rest home, assisted living and/or nursing facility within 90 days following discharge from an inpatient facility and no more than 9 times.)


name: Limited (30 minutes) in-home visit for an existing patient post-discharge. for use only in a medicare-approved cmmi model. (services must be furnished within a beneficiary's home, domiciliary, rest home, assisted living and/or nursing facility within 90 days following discharge from an inpatient facility and no more than 9 times.)


name: Moderate (45 minutes) in-home visit for an existing patient post-discharge. for use only in a medicare-approved cmmi model. (services must be furnished within a beneficiary's home, domiciliary, rest home, assisted living and/or nursing facility within 90 days following discharge from an inpatient facility and no more than 9 times.)


name: Comprehensive (60 minutes) in-home visit for an existing patient post-discharge. for use only in a medicare-approved cmmi model. (services must be furnished within a beneficiary's home, domiciliary, rest home, assisted living and/or nursing facility within 90 days following discharge from an inpatient facility and no more than 9 times.)


name: Extensive (75 minutes) in-home visit for an existing patient post-discharge. for use only in a medicare-approved cmmi model. (services must be furnished within a beneficiary's home, domiciliary, rest home, assisted living and/or nursing facility within 90 days following discharge from an inpatient facility and no more than 9 times.)


name: Limited (30 minutes) care plan oversight. for use only in a medicare-approved cmmi model. (services must be furnished within a beneficiary's home, domiciliary, rest home, assisted living and/or nursing facility within 90 days following discharge from an inpatient facility and no more than 9 times.)


name: Comprehensive (60 mins) home care plan oversight. for use only in a medicare-approved cmmi model. (services must be furnished within a beneficiary's home, domiciliary, rest home, assisted living and/or nursing facility within 90 days following discharge from an inpatient facility.)


name: Health care practitioners rendering treatment in place (tip)


name: A model participant (ambulance supplier/provider), the beneficiary refuses services covered under the model (transport to an alternate destination/treatment in place)


name: Medication assisted treatment, methadone; weekly bundle including dispensing and/or administration, substance use counseling, individual and group therapy, and toxicology testing, if performed (provision of the services by a medicare-enrolled opioid treatment program)


name: Medication assisted treatment, buprenorphine (oral); weekly bundle including dispensing and/or administration, substance use counseling, individual and group therapy, and toxicology testing if performed (provision of the services by a medicare-enrolled opioid treatment program)


name: Medication assisted treatment, buprenorphine (injectable) administered on a monthly basis; bundle including dispensing and/or administration, substance use counseling, individual and group therapy, and toxicology testing if performed (provision of the services by a medicare-enrolled opioid treatment program)


name: Medication assisted treatment, naltrexone; weekly bundle including dispensing and/or administration, substance use counseling, individual and group therapy, and toxicology testing if performed (provision of the services by a medicare-enrolled opioid treatment program)


name: Medication assisted treatment, weekly bundle not including the drug, including substance use counseling, individual and group therapy, and toxicology testing if performed (provision of the services by a medicare-enrolled opioid treatment program)


name: Medication assisted treatment, medication not otherwise specified; weekly bundle including dispensing and/or administration, substance use counseling, individual and group therapy, and toxicology testing, if performed (provision of the services by a medicare-enrolled opioid treatment program)


name: Intake activities, including initial medical examination that is conducted by an appropriately licensed practitioner and preparation of a care plan, which may be informed by administration of a standardized, evidence-based assessment, and that includes the patient's goals and mutually agreed-upon actions for the patient to meet those goals, including harm reduction interventions; the patient's needs and goals in the areas of education, vocational training, and employment; and the medical and psychiatric, psychosocial, economic, legal, housing, physical activity and/or nutrition needs and other recovery support services that a patient needs and wishes to pursue, conducted by an appropriately licensed/credentialed personnel (provision of the services by a medicare-enrolled opioid treatment program); list separately in addition to each primary code


name: Periodic assessment; assessing periodically by an otp practitioner and includes a review of moud dosing, treatment response, other substance use disorder treatment needs, responses and patient-identified goals, and other relevant physical, nutrition and psychiatric treatment needs and goals; may be informed by administration of a standardized, evidence-based assessment, or the need and interest for harm reduction interventions and recovery support services (provision of the services by a medicare-enrolled opioid treatment program); list separately in addition to each primary code


name: Take-home supply of methadone; up to 7 additional day supply (provision of the services by a medicare-enrolled opioid treatment program); list separately in addition to code for primary procedure


name: Take-home supply of buprenorphine (oral); up to 7 additional day supply (provision of the services by a medicare-enrolled opioid treatment program); list separately in addition to code for primary procedure


name: Each additional 30 minutes of counseling in a week of medication assisted treatment, (provision of the services by a medicare-enrolled opioid treatment program); list separately in addition to code for primary procedure


name: Patients age 66 and older in institutional special needs plans (snp) or residing in long-term care with a pos code 32, 33, 34, 54 or 56 for more than 90 days during the measurement period (G2081)


name: Office or other outpatient visit for the evaluation and management of an established patient that requires the supervision of a physician or other qualified health care professional and provision of up to 56 mg of esketamine nasal self-administration, includes 2 hours post-administration observation


name: Office or other outpatient visit for the evaluation and management of an established patient that requires the supervision of a physician or other qualified health care professional and provision of greater than 56 mg esketamine nasal self-administration, includes 2 hours post-administration observation


name: Office-based treatment for opioid use disorder, including development of the treatment plan, care coordination, individual therapy and group therapy and counseling; at least 70 minutes in the first calendar month


name: Office-based treatment for opioid use disorder, including care coordination, individual therapy and group therapy and counseling; at least 60 minutes in a subsequent calendar month


name: Office-based treatment for opioid use disorder, including care coordination, individual therapy and group therapy and counseling; each additional 30 minutes beyond the first 120 minutes (list separately in addition to code for primary procedure)


name: Angiotensin converting enzyme (ace) inhibitor or angiotensin receptor blocker (arb) or angiotensin receptor-neprilysin inhibitor (arni) therapy prescribed or currently being taken


name: Documentation of medical reason(s) for not prescribing ace inhibitor or arb or arni therapy (e.g., hypotensive patients who are at immediate risk of cardiogenic shock, hospitalized patients who have experienced marked azotemia, allergy, intolerance, other medical reasons)


name: Documentation of patient reason(s) for not prescribing ace inhibitor or arb or arni therapy (e.g., patient declined, other patient reasons)


name: Angiotensin converting enzyme (ace) inhibitor or angiotensin receptor blocker (arb) or angiotensin receptor-neprilysin inhibitor (arni) therapy was not prescribed, reason not given


name: Episodes where the patient had a competing diagnosis on or within three days after the episode date (e.g., intestinal infection, pertussis, bacterial infection, lyme disease, otitis media, acute sinusitis, chronic sinusitis, infection of the adenoids, prostatitis, cellulitis, mastoiditis, or bone infections, acute lymphadenitis, impetigo, skin staph infections, pneumonia/gonococcal infections, venereal disease (syphilis, chlamydia, inflammatory diseases [female reproductive organs]), infections of the kidney, cystitis or uti)


name: Patient receiving <=5 mg daily prednisone (or equivalent), or ra activity is worsening, or glucocorticoid use is for less than 6 months


name: Patient receiving >5 mg daily prednisone (or equivalent) for longer than 6 months, and improvement or no change in disease activity


name: Depression, anxiety, apathy, and psychosis assessed


name: Depression, anxiety, apathy, and psychosis not assessed


name: Patients 66 - 80 years of age with at least one claim/encounter for frailty during the measurement period and either one acute inpatient encounter with a diagnosis of advanced illness or two outpatient, observation, ed or nonacute inpatient encounters on different dates of service with an advanced illness diagnosis during the measurement period or the year prior to the measurement period (G2126)


name: Documentation of medical reason(s) for not on a daily aspirin or other antiplatelet (e.g. history of gastrointestinal bleed, intra-cranial bleed, blood disorders, idiopathic thrombocytopenic purpura (itp), gastric bypass or documentation of active anticoagulant use during the measurement period)


name: Procedure-related bp's not taken during an outpatient visit. examples include same day surgery, ambulatory service center, g.i. lab, dialysis, infusion center, chemotherapy


name: Back pain measured by the visual analog scale (vas) or numeric pain scale at three months (6 - 20 weeks) postoperatively was less than or equal to 3.0 or back pain measured by the visual analog scale (vas) or numeric pain scale within three months preoperatively and at three months (6 - 20 weeks) postoperatively demonstrated an improvement of 5.0 points or greater


name: Back pain measured by the visual analog scale (vas) or numeric pain scale at three months (6 - 20 weeks) postoperatively was greater than 3.0 and back pain measured by the visual analog scale (vas) or numeric pain scale within three months preoperatively and at three months (6 - 20 weeks) postoperatively demonstrated improvement of less than 5.0 points


name: Back pain as measured by the visual analog scale (vas) or numeric pain scale at one year (9 to 15 months) postoperatively was less than or equal to 3.0 or back pain measured by the visual analog scale (vas) or numeric pain scale within three months preoperatively and at one year (9 to 15 months) postoperatively demonstrated an improvement of 5.0 points or greater


name: Back pain measured by the visual analog scale (vas) or numeric pain scale at one year (9 to 15 months) postoperatively was greater than 3.0 and back pain measured by the visual analog scale (vas) or numeric pain scale within three months preoperatively and at one year (9 to 15 months) postoperatively demonstrated improvement of less than 5.0 points


name: Leg pain measured by the visual analog scale (vas) or numeric pain scale at three months (6 - 20 weeks) postoperatively was less than or equal to 3.0 or leg pain measured by the visual analog scale (vas) or numeric pain scale within three months preoperatively and at three months (6 - 20 weeks) postoperatively demonstrated an improvement of 5.0 points or greater


name: Leg pain measured by the visual analog scale (vas) or numeric pain scale at three months (6 - 20 weeks) postoperatively was greater than 3.0 and leg pain measured by the visual analog scale (vas) or numeric pain scale within three months preoperatively and at three months (6 - 20 weeks) postoperatively demonstrated improvement of less than 5.0 points


name: Functional status measured by the oswestry disability index (odi version 2.1a) at one year (9 to 15 months) postoperatively was less than or equal to 22 or functional status measured by the odi version 2.1a within three months preoperatively and at one year (9 to 15 months) postoperatively demonstrated an improvement of 30 points or greater


name: Functional status measured by the oswestry disability index (odi version 2.1a) at one year (9 to 15 months) postoperatively was greater than 22 and functional status measured by the odi version 2.1a within three months preoperatively and at one year (9 to 15 months) postoperatively demonstrated an improvement of less than 30 points


name: Functional status measured by the oswestry disability index (odi version 2.1a) at three months (6-20 weeks) postoperatively was less than or equal to 22 or functional status measured by the odi version 2.1a within three months preoperatively and at three months (6-20 weeks) postoperatively demonstrated an improvement of 30 points or greater


name: Functional status measured by the oswestry disability index (odi version 2.1a) at three months (6 - 20 weeks) postoperatively was greater than 22 and functional status measured by the odi version 2.1a within three months preoperatively and at three months (6 - 20 weeks) postoperatively demonstrated an improvement of less than 30 points


name: Leg pain as measured by the visual analog scale (vas) or numeric pain scale at one year (9 to 15 months) postoperatively was less than or equal to 3.0 or leg pain measured by the visual analog scale (vas) or numeric pain scale within three months preoperatively and at one year (9 to 15 months) postoperatively demonstrated an improvement of 5.0 points or greater


name: Leg pain measured by the visual analog scale (vas) or numeric pain scale at one year (9 to 15 months) postoperatively was greater than 3.0 and leg pain measured by the visual analog scale (vas) or numeric pain scale within three months preoperatively and at one year (9 to 15 months) postoperatively demonstrated improvement of less than 5.0 points


name: Documentation of medical reason(s) for not using multimodal pain management (e.g., allergy to multiple classes of analgesics, intubated patient, hepatic failure, patient reports no pain during pacu stay, other medical reason(s))


name: Documentation stating patient has a diagnosis of a degenerative neurological condition such as als, ms, or parkinson's diagnosed at any time before or during the episode of care (G2151)


name: Residual score for the neck impairment successfully calculated and the score was equal to zero (0) or greater than zero (> 0)


name: In hospice or using hospice services during the measurement period (G2153)


name: Patient received at least one dose of the herpes zoster live vaccine or two doses of the herpes zoster recombinant vaccine (at least 28 days apart) anytime on or after the patient's 50th birthday before or during the measurement period (G2160)


name: Patient received an influenza vaccine on or between july 1 of the year prior to the measurement period and june 30 of the measurement period (G2163)


name: Residual score for the neck impairment successfully calculated and the score was less than zero (< 0)


name: Residual score for the knee impairment not measured because the patient did not complete the lepf prom at initial evaluation and/or near discharge, reason not given


name: Residual score for the low back impairment not measured because the patient did not complete the low back fs prom at initial evaluation and/or near discharge, reason not given


name: Residual score for the shoulder impairment not measured because the patient did not complete the shoulder fs prom at initial evaluation and/or near discharge, reason not given


name: Residual score for the elbow, wrist or hand impairment not measured because the patient did not complete the elbow/wrist/hand fs prom at initial evaluation and/or near discharge, reason not given


name: Adult patients 18 years of age or older with major depression or dysthymia who did not reach remission at twelve months as demonstrated by a twelve month (+/-60 days) phq-9 or phq-9m score of less than 5. either phq- 9 or phq-9m score was not assessed or is greater than or equal to 5


name: Patient achieves final refraction (spherical equivalent) +/- 1.0 diopters of their planned refraction within 90 days of surgery


name: Patient does not achieve final refraction (spherical equivalent) +/- 1.0 diopters of their planned refraction within 90 days of surgery


name: Cystic renal lesion that is simple appearing (bosniak i or ii) , or adrenal lesion less than or equal to 1.0 cm or adrenal lesion greater than 1.0 cm but less than or equal to 4.0 cm classified as likely benign by unenhanced ct or washout protocol ct, or mri with in- and opposed-phase sequences or other equivalent institutional imaging protocols


name: Final reports for imaging studies stating no follow-up imaging is recommended


name: Documentation of medical reason(s) that follow-up imaging is indicated (e.g., patient has lymphadenopathy, signs of metastasis or an active diagnosis or history of cancer, and other medical reason(s))


name: Final reports for imaging studies with follow-up imaging recommended, or final reports that do not include a specific recommendation of no follow-up


name: Final reports for imaging studies without an incidentally found lesion noted


name: Patient has documentation of ventricular shunt, brain tumor, or coagulopathy


name: Pathology report diagnosing cutaneous basal cell carcinoma, squamous cell carcinoma, or melanoma (to include in situ disease) sent from the pathologist/ dermatopathologist to the biopsying clinician for review within 7 days from the time when the tissue specimen was received by the pathologist


name: Pathology report diagnosing cutaneous basal cell carcinoma, squamous cell carcinoma, or melanoma (to include in situ disease) was not sent from the pathologist/ dermatopathologist to the biopsying clinician for review within 7 days from the time when the tissue specimen was received by the pathologist


name: Documentation of advanced stage dementia and caregiver knowledge is limited


name: Leg pain was not measured by the visual analog scale (vas) or numeric pain scale at three months (6 - 20 weeks) postoperatively


name: Electronic positional obstructive sleep apnea treatment, with sensor, includes all components and accessories, any type


name: Low frequency ultrasonic diathermy treatment device for home use


name: Disposable collection and storage bag for breast milk, any size, any type, each


name: Knee ankle foot device, any material, single or double upright, swing and stance phase microprocessor control with adjustability, includes all components (e.g., sensors, batteries, charger), any type activation, with or without ankle joint(s), custom fabricated


name: Nipple prosthesis, custom fabricated, reusable, any material, any type, each


name: Functional status was not measured by the oswestry disability index (odi version 2.1a) at one year (9 to 15 months) postoperatively


name: Functional status was not measured by the oswestry disability index (odi version 2.1a) at three months (6 - 20 weeks) postoperatively


name: Leg pain was not measured by the visual analog scale (vas) or numeric pain scale at one year (9 to 15 months) postoperatively


name: Functional status was not measured by the oxford knee score (oks) or the knee injury and osteoarthritis outcome score joint replacement (koos, jr.) at one year (9 to 15 months) postoperatively


name: Initiated episode of rehabilitation therapy, medical, or chiropractic care for neck impairment


name: Blood component or product not otherwise classified


name: Dermacell, dermacell awm or dermacell awm porous, per square centimeter (add-on, list separately in addition to primary procedure)


name: Keramatrix or kerasorb, per square centimeter (add-on, list separately in addition to primary procedure)


name: Cellesta or cellesta duo, per square centimeter (add-on, list separately in addition to primary procedure)


name: Membrane graft or membrane wrap, per square centimeter (add-on, list separately in addition to primary procedure)


name: Novafix, per square cenitmeter (add-on, list separately in addition to primary procedure)


name: Surgraft, per square centimeter (add-on, list separately in addition to primary procedure)


name: Amnion bio or axobiomembrane, per square centimeter (add-on, list separately in addition to primary procedure)


name: Cellesta cord, per square centimeter (add-on, list separately in addition to primary procedure)


name: Artacent cord, per square centimeter (add-on, list separately in addition to primary procedure)


name: Woundfix, biowound, woundfix plus, biowound plus, woundfix xplus or biowound xplus, per square centimeter (add-on, list separately in addition to primary procedure)


name: Surgicord, per square centimeter (add-on, list separately in addition to primary procedure)


name: Surgigraft-dual, per square centimeter (add-on, list separately in addition to primary procedure)


name: Bellacell hd or surederm, per square centimeter (add-on, list separately in addition to primary procedure)


name: Amniowrap2, per square centimeter (add-on, list separately in addition to primary procedure)


name: Progenamatrix, per square centimeter (add-on, list separately in addition to primary procedure)


name: Myown skin, includes harvesting and preparation procedures, per square centimeter


name: Infectious disease (fungi), fungal pathogen identification, DNA (15 fungal targets), blood culture, amplified probe technique, each target reported as detected or not detected


name: Infectious disease (bacteria and fungi), gram-positive organism identification and drug resistance element detection, DNA (20 gram-positive bacterial targets, 4 resistance genes, 1 pan gram-negative bacterial target, 1 pan Candida target), blood culture, amplified probe technique, each target reported as detected or not detected


name: Infectious disease (bacteria and fungi), gram-negative bacterial identification and drug resistance element detection, DNA (21 gram-negative bacterial targets, 6 resistance genes, 1 pan gram-positive bacterial target, 1 pan Candida target), amplified probe technique, each target reported as detected or not detected


name: Infectious disease (bacteria, fungi, parasites, and DNA viruses), microbial cell-free DNA, plasma, untargeted next-generation sequencing, report for significant positive pathogens


name: Oncology (breast), mRNA, gene expression profiling by next-generation sequencing of 101 genes, utilizing formalin-fixed paraffin-embedded tissue, algorithm reported as a triple negative breast cancer clinical subtype(s) with information on immune cell involvement


name: Copy number (eg, intellectual disability, dysmorphology), sequence analysis


name: PMS2 (PMS1 homolog 2, mismatch repair system component) (eg, hereditary non-polyposis colorectal cancer, Lynch syndrome) mRNA sequence analysis (List separately in addition to code for primary procedure)


name: Hereditary colon cancer (Lynch syndrome), targeted mRNA sequence analysis panel (MLH1, MSH2, MSH6, PMS2) (List separately in addition to code for primary procedure)


name: Ramucirumab only product in parenteral dose form


name: Dapagliflozin and metformin and saxagliptin only product


name: Laparoscopic total colectomy and ileostomy


name: Laparoscopic total colectomy and loop ileostomy


name: Cardiopulmonary exercise test using arm ergometer


name: Cardiopulmonary exercise test using bicycle ergometer


name: Actinomyces meyeri or Actinomyces odontolyticus


name: Streptococcus anginosus or Streptococcus dysgalactiae


name: Streptococcus mitis or Streptococcus oralis or Streptococcus pneumoniae


name: Streptococcus acidominimus or Streptococcus pneumoniae


name: Lacticaseibacillus casei or Lacticaseibacillus paracasei


name: Neisseria flavescens or Neisseria subflava


name: Lysinibacillus fusiformis or Lysinibacillus sphaericus


name: Preoperative cardiopulmonary exercise test using arm ergometer


name: Preoperative cardiopulmonary exercise test using bicycle ergometer


name: Midazolam only product in nasal dose form


name: Yeast not Candida species and not Cryptococcus neoformans detected


name: Yeast not Candida albicans and not Cryptococcus neoformans detected


name: Yeast not Cryptococcus neoformans detected


name: Administration of prophylactic coagulation factor Xa inhibitor


name: Coagulation factor Xa inhibitor prophylaxis indicated


name: Administration of prophylactic direct thrombin inhibitor


name: Direct thrombin inhibitor prophylaxis indicated


name: Abnormal retraction of bilateral eyelids


name: Partial resection of small bowel using robotic assistance


name: Raoultella ornithinolytica or Raoultella planticola


name: Paenibacillus pabuli or Paenibacillus polymyxa


name: Bacillus circulans or Paenibacillus glucanolyticus


name: Klebsiella pneumoniae subspecies pneumoniae or Raoultella planticola


name: Alpha-tocopherol and selenium only product


name: Alpha-tocopherol and selenium only product in oral dose form


name: Chromogenic in situ hybridization technique


name: Silver enhanced in situ hybridization technique


name: Anaplastic lymphoma kinase staining method


name: Alpha-tocopherol and gamolenic acid only product


name: Radium-223-containing product in parenteral dose form


name: Radium-223 only product in parenteral dose form


name: Clonorchis species or Opisthorchis species


name: Alpelisib only product in oral dose form


name: Accidental excessive dose of vaccine administered


name: Intentional excessive dose of vaccine administered


name: Excessive dose of vaccine administered with undetermined intent


name: Cystic fibrosis transmembrane conductance regulator-related metabolic syndrome


name: History of anal intraepithelial neoplasia III


name: History of benign neoplasm of salivary gland


name: Excessive dose of gamma globulin administered


name: Accidental excessive dose of gamma globulin administered


name: Excessive dose of gamma globulin administered with undetermined intent


name: Intentional excessive dose of gamma globulin administered


name: Excessive dose of antiserum administered


name: Accidental excessive dose of antiserum administered


name: Excessive dose of antiserum administered with undetermined intent


name: Intentional excessive dose of antiserum administered


name: History of benign phyllodes neoplasm of breast


name: History of bilateral shoulder arthroplasty


name: History of Descemet's membrane endothelial keratoplasty


name: History of repair of congenital cleft palate


name: Papiliotrema laurentii or Rhodotorula glutinis or Rhodotorula mucilaginosa


name: Geobacillus thermodenitrificans or Parageobacillus thermoglucosidasius


name: Cyanocobalamin and folic acid and pyridoxine only product


name: Bilateral localized swelling of finger of hands


name: Deep-tissue electromagnetic stimulation system


name: Back performance-feedback physical therapy system


name: Ultrasonography of biliary tract abnormal


name: Polatuzumab vedotin only product in parenteral dose form


name: Egg of Heterophyes heterophyes or egg of Metagonimus yokogawai


name: PET myocardial rest imaging using rubidium-82


name: PET with CT myocardial stress imaging using rubidium-82


name: PET myocardial stress imaging using rubidium-82


name: PET with CT myocardial rest imaging using rubidium-82


name: Bilateral mass of soft tissue of upper limbs


name: Mammographic bilateral calcification of breasts


name: Bremelanotide only product in parenteral dose form


name: Paranasal sinus irrigation/aspiration cannula


name: Multiple-pronged submucosal injection needle


name: Tumor therapy nanoparticle thermo-magnetic activation thermometry catheter


name: OnabotulinumtoxinA only product in parenteral dose form


name: Assessment using Griffith Mental Development Scale


name: Acquired enlargement of ventricle of brain


name: Endoscopic ultrasonography guided insertion of fiducial marker into pancreas


name: Endoscopic ultrasonography guided fine needle aspiration of pancreatic lesion


name: Pediatric chronic pain management service


name: Geriatric chronic pain management service


name: Narcotic addiction service with chronic pain management


name: Disinfection of room using ultraviolet room disinfection system


name: Fluoroscopy guided lithotripsy of bilateral kidneys


name: Pediatric chronic pain management specialty


name: Narcotic addiction medicine specialty with chronic pain management


name: Geriatric chronic pain management specialty


name: Plasma specimen or serum specimen or whole blood specimen


name: MRI-US fusion guided transperineal biopsy of prostate


name: MRI-US fusion guided transrectal biopsy of prostate


name: Selinexor only product in oral dose form


name: Stereotactic radiosurgical gamma radiation system


name: Corticosteroid and/or corticosteroid derivative therapy


name: Gadobutrol-containing product in oral dose form


name: Gadobutrol only product in oral dose form


name: Bronchoscopic microwave ablation of lesion of lung


name: Requires vaccination against arthropod-borne viral encephalitis


name: Requires vaccination against cholera with typhoid-paratyphoid


name: Requires vaccination against diphtheria-tetanus-pertussis with poliomyelitis


name: Requires vaccination against diphtheria-tetanus-pertussis with typhoid-paratyphoid


name: Requires vaccination against leishmaniasis


name: Requires vaccination against viral hepatitis


name: Requires vaccination against typhoid-paratyphoid


name: History of pain at rest due to peripheral vascular disease


name: Cilastatin and imipenem and relebactam only product


name: Cilastatin and imipenem and relebactam only product in parenteral dose form


name: Glucagon only product in nasal dose form


name: Close up photographic view of teeth with no set magnification or distance


name: Mirrored visible image uncorrected flipped horizontally and vertically


name: Mirrored visible image uncorrected flipped vertically


name: Apremilast only product in oral dose form


name: Implantation of dental prosthesis into jaw


name: Darolutamide only product in oral dose form


name: Ultrasonography guided erector spinae plane block


name: Photographic image with mouth partially opened position and teeth apart


name: Mirrored visible image uncorrected flipped horizontally


name: Pexidartinib only product in oral dose form


name: Estimated quantity of intake of phosphorous in 24 hours


name: Estimated quantity of intake of magnesium in 24 hours


name: Family history of acetylcholinesterase deficiency


name: Albumin human only product in parenteral dose form


name: Estimated quantity of intake of fat and oil via oral route in 24 hours


name: Estimated quantity of intake of fat and oil via enteral route in 24 hours


name: Estimated quantity of intake of carbohydrate via oral route in 24 hours


name: Estimated quantity of intake of carbohydrate via enteral route in 24 hours


name: Estimated quantity of intake of carbohydrate via intravenous route in 24 hours


name: Mirrored photographic image of teeth corrected flipped horizontally


name: Mirrored photographic image of teeth corrected flipped vertically


name: Mirrored photographic image of teeth corrected flipped vertically and horizontally


name: Photographic image of face with lips in relaxed position


name: Pretomanid only product in oral dose form


name: Estimated intake of vegetable servings in 24 hours


name: Estimated quantity of intake of water via oral route in 24 hours


name: Measured quantity of intake of water via oral route in 24 hours


name: Estimated quantity of intake of fluoride in 24 hours


name: Estimated quantity of intake of copper in 24 hours


name: Estimated quantity of intake of polyunsaturated fat in 24 hours


name: Estimated quantity of intake of linoleic acid in 24 hours


name: Estimated quantity of intake of monounsaturated fat in 24 hours


name: Estimated quantity of intake of iron in 24 hours


name: Estimated quantity of intake of iodine in 24 hours


name: High intensity sweetener additive intake


name: Excessive intake of high intensity sweetener additive


name: Estimated total quantity of intake of trans fatty acids in 24 hours


name: Pitolisant only product in oral dose form


name: Entrectinib only product in oral dose form


name: Fedratinib only product in oral dose form


name: Estimated oral intake of beverage with high intensity sweetener estimated in 24 hours


name: Estimated oral intake of 100 percent fruit juice in 24 hours


name: Estimated oral intake of caffeinated beverages in 24 hours


name: Measured oral intake of 100 percent fruit juice in 24 hours


name: Tegaserod only product in oral dose form


name: Liraglutide only product in parenteral dose form


name: Estimated oral intake of liquid dairy product in 24 hours


name: Measured oral intake of nutritionally complete liquid supplement in 24 hours


name: Estimated oral intake of liquid meal replacement in 24 hours


name: Measured oral intake of liquid dairy product in 24 hours


name: Latanoprost- and netarsudil-containing product in parenteral dose form


name: Latanoprost and netarsudil only product in parenteral dose form


name: Measured oral intake of liquid meal replacement in 24 hours


name: Upadacitinib only product in oral dose form


name: Onasemnogene abeparvovec only product in parenteral dose form


name: Decompression of small intestine via colonoscope


name: Caplacizumab only product in parenteral dose form


name: History of aneurysm of peripheral artery


name: Esketamine only product in nasal dose form


name: Lefamulin only product in oral dose form


name: Lefamulin only product in parenteral dose form


name: Estimated intake of empty energy servings in 24 hours


name: Estimated quantity of intake of sulfate salt in 24 hours


name: Estimated intake of fat servings in 24 hours


name: Estimated intake volume of breast milk in 24 hours


name: Measured volume of intake of breast milk in 24 hours


name: Postcoital oral contraceptive prescribed


name: Istradefylline only product in oral dose form


name: Insulin dose at evening meal calculated by insulin to carbohydrate ratio


name: Insulin dose calculated by insulin sensitivity factor


name: Insulin dose calculated by insulin to carbohydrate ratio


name: Insulin dose at breakfast calculated by insulin to carbohydrate ratio


name: Insulin dose at lunch calculated by insulin sensitivity factor


name: Insulin dose at lunch calculated by insulin to carbohydrate ratio


name: Eye and eyelid movement monitoring spectacles


name: Mother has harmful pattern of alcohol use


name: Measured volume of intake per kilogram body weight of breast milk in 24 hours


name: Diagnostic intravenous injection of edrophonium


name: Contraceptive intrauterine device retained


name: Para-aminosalicylate only product in oral dose form


name: Timed unsupported steady stand technique


name: Past pregnancy history of placental abruption


name: Colonoscopy and fecal microbiota transplantation


name: Sigmoidoscopy and fecal microbiota transplantation


name: Ureterorenoscopy with fragmentation and removal of calculus of kidney


name: Estimated intake of protein food servings in 24 hours


name: Video assisted thoracoscopy for control of hemorrhage


name: Pulse present in right posterior tibial artery


name: Pulse present in right anterior tibial artery


name: Pulse present in left anterior tibial artery


name: Pulse present in left posterior tibial artery


name: Inadequate intake of folate and/or folate derivative


name: Excessive intake of folate and/or folate derivative


name: Pulse present in right dorsalis pedis artery


name: Pulse present in left dorsalis pedis artery


name: Normal pulse in right posterior tibial artery


name: Normal pulse in left posterior tibial artery


name: All pulses present in bilateral lower limbs


name: Pulse in left anterior tibial artery absent


name: Pulse in right anterior tibial artery absent


name: Pulse in right posterior tibial artery absent


name: Pulse in left posterior tibial artery absent


name: Caffeinated beverage measured oral intake in 24 hours


name: Estimated quantity of intake of protein and/or protein derivative in 24 hours


name: Tenapanor only product in oral dose form


name: Drug addiction therapy using buprenorphine and naloxone


name: Drug addiction therapy using buprenorphine


name: Placement of orthodontic bracket using partial bonding


name: Aluminum hydroxide and dimethicone and magnesium hydroxide only product


name: Aluminum hydroxide and dimethicone only product


name: Bovine isophane insulin only product in parenteral dose form


name: Calcium carbonate and dimethicone only product


name: Dimethicone and hydrotalcite only product


name: Insulin aspart and insulin aspart protamine only product


name: Insulin lispro and insulin lispro protamine only product


name: Dimethicone and pipenzolate only product


name: Pituitary follicle stimulating hormone only product


name: Pituitary follicle stimulating hormone only product in parenteral dose form


name: Dimethicone and sodium bicarbonate only product


name: Normal pulse in left dorsalis pedis artery


name: Normal pulse in right dorsalis pedis artery


name: Disproportion between fetus and pelvis due to conjoined twins


name: Past pregnancy history of shoulder dystocia


name: Beverage containing high intensity sweetener


name: Medical Dictionary for Regulatory Activities simple map module


name: Estimated percent of meals eaten in 24 hours


name: Measured percent of meals eaten in 24 hours


name: Fasting pattern in one calendar day, reported


name: Fasting pattern in one calendar month, reported


name: Fasting pattern in one calendar year, reported


name: Adjust fixed orthodontic expansion appliance


name: Endovascular repair of aneurysm using fenestrated branched endovascular stent graft


name: Rinsing of mouth using fluoride treatment


name: Vascularized bone graft to spine with microsurgery


name: Vascularized bone graft to pelvis with microsurgery


name: Administration of ergometrine and oxytocin


name: Echocardiography using pharmacologic stress agent


name: Trifarotene only product in cutaneous dose form


name: Baloxavir only product in oral dose form


name: Estimated oral intake of sugar sweetened drinks in 24 hours


name: Measured oral intake of sugar sweetened drinks in 24 hours


name: Infant formula intake measured volume per kg in 24 hours


name: Nutritionally complete liquid supplement


name: Nutritionally complete liquid supplement estimated oral intake in 24 hours


name: Intake of maternal expressed breast milk


name: At increased risk of emergency hospital admission


name: Assessment using Healthy Eating Index 2015


name: Estimated quantity of intake of ascorbic acid in 24 hours


name: Estimated quantity of intake of vitamin D and/or vitamin D derivative in 24 hours


name: Estimated quantity of intake of vitamin E and/or vitamin E derivative in 24 hours


name: Estimated quantity of intake of vitamin K and/or vitamin K derivative in 24 hours


name: Estimated quantity of intake of thiamine in 24 hours


name: Estimated quantity of intake of riboflavin in 24 hours


name: Estimated quantity of intake of niacin in 24 hours


name: Estimated quantity of intake of folate and/or folate derivative in 24 hours


name: Estimated quantity of intake of vitamin B6 and/or vitamin B6 derivative in 24 hours


name: Estimated quantity of intake of vitamin B12 and/or vitamin B12 derivative in 24 hours


name: Estimated quantity of intake of pantothenic acid in 24 hours


name: Estimated quantity of intake of biotin in 24 hours


name: Estimated quantity of intake of calcium in 24 hours


name: Estimated quantity of intake of potassium in 24 hours


name: Estimated quantity of intake of sodium in 24 hours


name: Estimated quantity of intake of zinc in 24 hours


name: Brolucizumab only product in parenteral dose form


name: Pedicle vascularized bone graft to fibula


name: Finding of abdominopelvic segment of trunk


name: Plastic repair of aortic arch with tube graft


name: Pedicle vascularized bone graft to iliac crest


name: Transmission of light blocked by swelling of scrotum


name: Estimated quantity of intake of vitamin A and/or vitamin A derivative in 24 hours


name: Nutrition self monitoring at agreed upon rate


name: Nutrition self management as agreed upon


name: Measured quantity of intake of protein and/or protein derivative via oral route in 24 hours


name: Measured quantity of intake of protein and/or protein derivative via enteral route in 24 hours


name: Estimated quantity of intake of fat and oil in 24 hours


name: Estimated quantity of intake of N-3 fatty acid in 24 hours


name: Dullness of light reflex at tympanic membrane


name: Arterial pressure index within reference range


name: Insertion of removable orthodontic space maintainer


name: Esophagogastroduodenoscopy and fecal microbiota transplant


name: Ventricular inversion electrocardiogram pattern


name: Elexacaftor and ivacaftor and tezacaftor only product


name: Elexacaftor and ivacaftor and tezacaftor only product in oral dose form


name: Movement of mass of abdomen on respiration


name: Lasmiditan only product in oral dose form


name: Mass of abdomen still during respiration


name: Pulse in right dorsalis pedis artery absent


name: Pulse in left dorsalis pedis artery absent


name: Insertion of fixed rapid mandibular expansion appliance


name: Insertion of orthodontic anchoring screw


name: Pelvic floor exercise biofeedback device


name: Ventricular circulatory assist valved catheter


name: Indwelling urethral or suprapubic drainage catheter


name: Fetal inflatable sleeve extraction system


name: Silicone gel-filled polyurethane foam covered surface breast implant


name: Guided periodontal tissue regeneration re-entry


name: At increased risk of malignant hyperthermia


name: At increased risk of cardiovascular disease


name: Doravirine/ Lamivudine/ Tenofovir Disproxil Fumarate


name: Anti-HIV Agents, Protease Inhibitors (PI)


name: Darunavir/ Cobicistat/ Emtricitabine/ Tenofovir Alafenamide Fumarate


name: Alogliptin Benzoate/ Pioglitazone Hydrochloride


name: Calcium Channel Blocking Agents, Dihydropyridines


name: Calcium Channel Blocking Agents, Nondihydropyridines


name: Amlodipine Besylate/ Atorvastatin Calcium


name: Olmesartan Medoxomil/ Amlodipine Besylate/ Hydrochlorothiazide


name: Dextromethorphan Hydrobromide/ Quinidine Sulfate


name: Neomycin/ Polymyxin B Sulfates/ Bacitracin Zinc/ Hydrocortisone


name: Polyethylene Glycol 3350/ Sodium Chloride/ Sodium Bicarbonate/ Potassium Chloride/ Bisacodyl


name: Genetic or Enzyme or Protein Disorder: Replacement, Modifiers, Treatment


name: Adenovirus Type 4 and Type 7 Vaccine Live


name: Tetanus and Diphtheria Toxoids Adsorbed (Td)


name: Hepatitis A and Hepatitis B (Recombinant) Vaccine


name: Ophthalmic Beta-Adrenergic Blocking Agents


name: Ophthalmic Intraocular Pressure Lowering Agents, Other


name: Neomycin/ Polymyxin B Sulfates/ Bacitracin Zinc/ Hydrocortisone Acetate


name: Neomycin/ Polymyxin B Sulfates/ Dexamethasone


name: Neomycin/ Polymyxin B Sulfates/ Hydrocortisone


name: Azelastine Hydrochloride/ Fluticasone Propionate


name: Umeclidinium Bromide/ Vilanterol Trifenatate


name: Fluticasone Furoate/ Umeclidinium Bromide/ Vilanterol Trifenatate


name: Dopamine Precursors and/or L-Amino Acid Decarboxylase Inhibitors


name: LUNG FUNCTION, SMOKING-RELATED ACCELERATED RATE OF DECLINE IN


name: GLS, (GCA)n REPEAT EXPANSION, 5-PRIME UTR


name: HOXA13, GLN50LEU AND 2-BP DEL, -79GC, PROMOTER


name: HOXA13, 18-BP DUP, ALANINE TRACT EXPANSION


name: HOXA13, 27-BP DUP, ALANINE TRACT EXPANSION


name: HOXA13, 42-BP DUP, ALANINE TRACT EXPANSION


name: HOXD13, 27-BP DUP, ALANINE TRACT EXPANSION


name: MARS1, SER567LEU (dbSNP rs143592405) AND ALA393THR (dbSNP rs141340466)


name: ARX, 21-BP DUP, ALANINE TRACT EXPANSION, EX2


name: SOX3, 33-BP DUP, NT711-743, ALANINE TRACT EXPANSION


name: SOX3, 21-BP DUP, NT720, ALANINE TRACT EXPANSION


name: RUNX2, 30-BP DUP, ALANINE TRACT EXPANSION


name: CACNA1A, (CAG)n REPEAT EXPANSION, 21-30 REPEATS, EX47


name: CSTB, (CCCCGCCCCGCG)n REPEAT EXPANSION, 12-MER REPEAT EXPANSION, PROMOTER REGION


name: ATXN2, (CAG)n REPEAT EXPANSION, INTERMEDIATE


name: TBX1, 30-BP DUP, NT1399, ALANINE TRACT EXPANSION


name: ZIC2, 30-BP INS, ALANINE TRACT EXPANSION


name: FOXL2, 15-BP INS, NT921, ALANINE TRACT EXPANSION


name: XYLT1, (GGC)n REPEAT EXPANSION, PROMOTER


name: DIP2B, CGG(n) REPEAT EXPANSION, 5-PRIME UTR


name: MARCHF6, TTTCA(n) REPEAT EXPANSION, IVS1


name: ATP5MD, IVS3DS, G-C, +1 (dbSNP rs146599698)


name: PABPN1, (GCG)n REPEAT EXPANSION, (GCG)8-13


name: Esophageal indentation on barium swallow


name: Retarded ossification of lower spine and digits


name: Absent radii and fibulae with boomerang shaped remaining long bones


name: Segmental demyelination/remyelination seen on nerve biopsy


name: Calcium pyrophosphate dihydrate (CPPD) crystal deposition (knee, symphysis pubis, wrist)


name: Little or no eyebrows, eyelashes or body hair


name: Coarse, wiry, twisted hair in early childhood


name: Lentigines, 1-5mm, dark (especially neck and trunk)


name: Adult-onset metachromatic leukodystrophy variant


name: Diastasis of the right sternoclavicular joint


name: 'Double contour' convolutional calcification seen on CT scan


name: Hemangiomata (in at least first branch (ophthalmic) of trigeminal nerve distribution, unilateral, occasionally bilateral)


name: Disturbed bladder and ureter coordination, neurogenic


name: Abnormal initial QRS vector (delta wave)


name: No hair in hair follicles on skin biopsy


name: Reduced or nondetectable electroretinogram (ERG)


name: Significantly reduced or absent scotopic and photopic responses seen on ERG


name: Dysmorphic features, subtle and nonspecific


name: Basal lamina 'onion bulb' formations seen on nerve biopsy


name: Normal-sized to hypoplastic or absent thyroid gland


name: Low to no uptake on thyroid scintigraphy


name: Delayed intellectual development (if untreated)


name: Decrease or absence of cytochrome c oxidase seen on muscle biopsy


name: Abundant intracytoplasmic glycogen seen on EM of renal tubular cells


name: Abundant intracytoplasmic glycogen seen on EM of hepatocytes


name: Normal red cell galactose-1-phosphate uridyltransferase


name: Decreased signal intensity in the pallidal nuclei with central hyperintensity ('eye of the tiger' sign) seen on MRI


name: Tightening of the Sylvian fissure on brain imaging


name: Villus blunting, mild, seen on duodenal biopsy


name: Hyperplasia of duodenal crypt epithelium, mild


name: Cytoplasmic vacuolation of duodenal surface epithelium


name: Thrombocytopenia, mild to moderate, episodic or persistent


name: Focal separation of keratinocytes above the basal layer


name: Increased numbers of basophilic vesicles in proliferative layers of epidermis


name: 'Butterfly-like' contour of midbrain seen on MRI


name: Disrupted corticospinal tract projections


name: Microcephaly, progressive (down to -8 SD)


name: Behavioral problems, severe, at age 3-4 years


name: Behavioral problems, severe, beginning at 3 to 4 years of age


name: Small, membrane-bound vacuoles predominantly in type 2 fibers


name: Familial aggregation without simple mendelian pattern


name: Type I fiber predominance seen on muscle biopsy


name: Giant axonal swellings filled with densely packed bundles of 10-nm neurofilaments seen on sural nerve biopsy


name: Normal psychomotor development until age 1 to 3 years


name: Sarcoplasmic PAS-positive vacuoles seen on muscle biopsy


name: Glycogen accumulation in myofibrils and lysosomes


name: Loss of visual acuity, moderate central, in males (20/60)


name: Nonspecific changes seen on electroretinogram in carrier females


name: Hypertrophic cardiomyocytes seen on biopsy


name: Vacuolated cytoplasm with degenerated mitochondria, glycogen, and granular debris


name: Decreased visual acuity (in early childhood)


name: Nondetectable responses seen on electroretinography


name: Increased susceptibility to EBV-associated B-cell lymphoproliferative disorders


name: Increased susceptibility to viral infections, variable


name: Decreased NKG2D expression on NK and CD8+ T cells


name: Respiratory infections, recurrent, bacterial and viral


name: Elevated or inappropriately normal thyroid stimulating hormone (TSH)


name: Diminished TSH response to TRH stimulation


name: Type 1 pattern of abnormal serum transferrin isoelectric focusing consistent with a glycosylation defect


name: Inappropriately normal thyroid-stimulating hormone level


name: Diffuse white matter hyperintensities seen on T2-weighed imaging


name: Ragged-red fibers with decreased COX activity seen on muscle biopsy


name: Lipid accumulation seen on muscle biopsy


name: Abnormal mitochondria with disorganized and vacuolated cristae seen on electron microscopy


name: Diffuse white matter abnormalities seen on brain imaging


name: Peripheral fundus bone spicule formation


name: Head circumference less than 32 cm (range 30-32cm)


name: T2-weighted with high-intensity lesions in the cerebral white matter


name: White matter abnormalities at corticomedullary junctions


name: White matter abnormalities in the corpus callosum


name: White matter abnormalities in the cerebellum


name: Distal muscle weakness (may affect bulbar regions)


name: Eosinophilic intranuclear inclusions in various cells, including adipocytes, muscle cells, Schwann cells, sweat gland cells, and vascular smooth muscle cells


name: Inclusions stain positively for ubiquitin and p62 (SQSTM1)


name: Aortic root dimension within normal range with no progression


name: Atrioventricular block, partial or complete


name: Circumferential fibrosis (in late-stage disease)


name: Desmin aggregates seen in ventricular myocardium


name: Rare 'onion bulb' formations seen on nerve biopsy


name: Severe hypomyelination seen on nerve biopsy


name: Reduction of voluntary recruitment seen on EMG


name: Involuntary rhythmic myoclonic movements (distal extremities, usually fingers)


name: Electrophysiologic studies indicate cortical origin of the abnormal movements


name: Seizures, focal, partial, often hemifacial


name: Rolandic sharp waves and spikes seen on EEG


name: Overwhelming activation of T lymphocytes and macrophages associated with fever


name: Activated (HLA DR+) CD8+ T lymphocytes in peripheral blood


name: Defective anti CD3-driven cytotoxic T-cell activity


name: Hemophagocytosis (in bone marrow or cerebrospinal fluid)


name: Type 1 fiber predominance and hypertrophy


name: Core-like regions devoid of oxidative activity seen on muscle biopsy


name: Myofibrillar changes seen on muscle biopsy


name: Pleomorphic hyaline, granular, and amorphous deposits that stain with Gomori trichrome


name: Fatty infiltration of affected muscles seen on MRI


name: Dilated superficial facial and abdominal veins


name: Bronchiectasis due to poor ciliary clearance


name: Increased connective tissue and fat seen on MRI


name: Absent distal and absent/hypoplastic middle phalanges (fingers IV and V more severely affected than fingers II and III, intermediate phenotype)


name: Cranial nerve palsy, intermittent, transient


name: Spasticity (primarily lower limbs, but upper limbs may be involved)


name: Disturbances of pigment in retinal pigment epithelium (RPE)


name: Grayish-white discoloration in periphery and midperiphery


name: Bone spicule-shaped deposits in midperiphery


name: Reduced amplitude of both rods and cones seen on ERG


name: Atrophic and ill-defined retinal layers seen on optical coherence tomography (OCT)


name: Arteriovenous malformation, progressive, with cutaneous involvement


name: Subclavian artery aneurysm (in homozygotes)


name: Innominate artery aneurysm (in homozygotes)


name: Carotid artery aneurysm (in homozygotes)


name: Elfin appearance (seen in recessive form)


name: Extensive folding and redundant skin (present at birth)


name: Redundant skin (present at birth, improves over time)


name: Skin folds (present on abdomen and arms)


name: Wrinkled skin (present on backs of hands and wrists)


name: Structural brain anomalies Schizencephaly


name: Exaggerated startle response (to tactile or acoustic stimuli)


name: Demyelination seen on sural nerve biopsy


name: Involuntary rhythmic myoclonic movements ('tremor', upper extremities)


name: Spike and wave or polyspike and wave discharges seen on EEG


name: Increased risk of acute myeloid leukemia, particularly associated with R882 mutations


name: Myopathic changes, mild, seen on muscle biopsy


name: Decreased heparan sulfate levels in blood and urine


name: Liver failure, acute, episodic, during first decade


name: Elevated liver enzymes during acute episodes


name: Liver enzymes tend to normalize after acute episode


name: Central or eccentric oxidative accumulations in muscle fibers


name: Disorganized myofibrils on electron microscopy


name: Increased height of the vertebral bodies


name: Abnormal signals in the striatum seen on brain imaging


name: Muscle weakness, distal, upper and lower limbs, due to neuropathy


name: Muscle atrophy, distal, upper and lower limbs, due to neuropathy


name: Reduced density and thickness of myelin fibers seen on sural nerve biopsy


name: Elevated mevalonate lactone, methylsuccinate and multiple branched-chain dicarboxylic acids


name: Reduced low-density lipoprotein cholesterol (LDL-C)


name: Lack of hair pigment seen on light and electron microscopy


name: Oocytes have thin or absent zona pellucida


name: Nonobstructive azoospermia (in the brother of an affected sister)


name: Impaired activities of mitochondrial respiratory chain complexes


name: Brain imaging abnormalities, variable, nonspecific


name: Tremor, resting and intentional, high-frequency


name: Globally impaired myelination seen on MRI


name: Slight atrophic progression of cerebral hemispheres


name: Slight atrophic progression of corpus callosum


name: Nonprogressive hypomyelination posterior limb of internal capsule


name: Nonprogressive hypomyelination in optic radiation


name: Nystagmus, horizontal high-frequency low-amplitude


name: Progressive difficulty with night vision


name: Thinning of peripapillary retinal nerve fiber layer seen on SD-OCT


name: Ichthyotic scales within first year of life


name: Hyperkeratotic skin, especially over extensor surfaces


name: Acanthosis nigricans (nuchal, axillary, umbilical)


name: Numerous lysosomes filled with lipopigment


name: Microvesicular steatosis seen on liver biopsy


name: Coagulation defects secondary to liver dysfunction


name: Erythematous hyperkeratotic plaques on dorsal surface of extremities


name: Erythematous hyperkeratotic plaques on periorificial areas


name: Perivascular lymphocytic infiltration, mild, in superficial dermis


name: Eczematous lesions on hands and feet (in adulthood)


name: Abnormally heterogeneous water content pattern in stratum corneum


name: Decreased muscle mass in lower extremities


name: Abnormal cytoplasmic inclusion bodies in renal interstitial macrophages


name: Abnormal cytoplasmic inclusion bodies in hepatic macrophages


name: Abnormal cytoplasmic inclusion bodies in duodenal histiocytes


name: Diffuse hypermobility of upper extremities


name: Enlarged lysosomal storage vacuoles in liver, spleen, and kidney


name: Abnormal cytoplasmic inclusion bodies in interstitial macrophages


name: Alternating light and dark banding pattern ('tiger tail') seen under polarization microscopy


name: Oocyte death before and/or after fertilization


name: Bone spicule-like pigmentation in retinal periphery


name: Reduced but relatively preserved cone responses


name: Variable epileptiform discharges seen on EEG


name: Focal disruptions of the basement membrane of small vessels


name: Thickened basement membrane of small vessels


name: Abnormal accumulation of extracellular matrix proteins in the subendothelial spaces between vascular smooth muscle cells of small vessels


name: Disconnection and degeneration of vascular smooth muscle cells


name: Increased fibrosis of the walls of small venules


name: Status epilepticus (at age 4 following febrile illness)


name: No acquisition of language milestones Cerebral atrophy


name: 40% reduction of mtDNA copy number seen on muscle biopsy


name: Reduced or absent pituitary response to thyrotropin-releasing hormone (TRH) stimulation


name: Mild and nonspecific changes seen on muscle biopsy


name: Impaired intellectual development (IQ 35-50)


name: Shortened sleep cycle (average 5.7 hours per night)


name: Diffuse mesangial sclerosis on renal biopsy


name: Loss of gross and fine motor skills in infancy


name: Bone spicule-like pigmentation in mid-periphery


name: Atrophy of outer retinal layers seen on SD-OCT


name: Preservation of foveal photoreceptors seen on SD-OCT


name: Hyperautofluorescent ring seen on FAF imaging


name: Severely reduced to absent rod responses seen on ERG


name: Moderately reduced to absent cone responses seen on ERG


name: Mild irregularity of vertebral endplates at thoracolumbar junction


name: Delayed epiphyseal ossification of proximal femur


name: Premature degenerative joint disease (in adulthood)


name: Disorganized layers of the cerebral cortex on histology


name: Microcephaly, congenital, progressive (down to -7 SD)


name: Punctate sclerotic foci at multiple metaphyses


name: Reduced scotopic rod responses seen on electroretinography (ERG)


name: Reduced scotopic combined responses seen on ERG


name: Relative preservation of photopic responses seen on ERG


name: Neuroregression, particularly of motor skills


name: Abnormal signals at the corticomedullary junction on diffusion weighted imaging


name: Nonspecific myopathic changes on skeletal muscle biopsy


name: Abnormal liver enzymes during acute episode


name: Liver enzymes may return to normal between episodes


name: Abnormal mitochondrial sheath seen on transmission electron microscopy


name: Cytoplasmic bags containing unassembled flagellar components


name: Multiple rib fractures (at birth and postnatally)


name: Multiple fractures (at birth and postnatally)


name: Contractures of 2nd and 3rd fingers, bilateral


name: Structural abnormalities of the basal ganglia on brain imaging


name: Agenesis of the putamen and globi pallidi


name: Abnormal course of corticospinal tracts in the brainstem


name: Increased susceptibility to septic shock


name: Lymphocytes may be decreased during infection


name: Decreased immunoglobulin levels, variable


name: Impaired T-cell lymphoproliferative response to stimulation, mild


name: Semilobar holoprosencephaly seen on brain imaging


name: Diffuse white matter hyperintensity seen on MRI


name: Duplicated collecting system, unilateral


name: Dilated right and left branches of pulmonary artery


name: Structured subsarcolemmal core lesions in type 1 fibers


name: Core-like lesions with decreased oxidative activity


name: Impaired activity of glutathione reductase


name: Intractable malabsorptive diarrhea, congenital


name: Multifocal spike discharges Poor or absent psychomotor development


name: Disorganized or absent doublet microtubules


name: Hydrocephalus apparent on prenatal ultrasound


name: Dysmorphic facial features, highly variable


name: Generalized epileptic activity seen on EEG


name: Lissencephaly, posterior to anterior gradient seen on MRI


name: In-folding of gyri in the mesial occipital cortex


name: Neurologic regression, episodic, associated with illness, stress, or fever


name: Hyperintense lesions in the basal ganglia and brainstem


name: Altered mitochondria with abnormal cristae seen on muscle biopsy


name: Normal mitochondrial respiratory enzyme activity in patient fibroblasts


name: Decreased ATP production in patient fibroblasts


name: Hypomyelinating leukodystrophy, infantile-onset, transient


name: Enlarged ventricles, mild, due to arrested hydrocephalus


name: Patient respiratory epithelial cells have reduced or absent motile cilia and basal bodies


name: Infections of the upper and lower airways, recurrent


name: Progression to hand-movement-only vision


name: Bone-spicule pigmentary deposits in midperiphery


name: Nummular pigmentary deposits in midperiphery


name: Relative preservation of anterior retina


name: Reduced vision in midperipheral fields seen on Goldmann perimetry


name: Reduced to nonrecordable rod-isolated responses seen on ERG


name: Reduced to nonrecordable mixed rod and cone responses


name: Enlarged ventricles due to hydrocephalus


name: Abnormal cytoplasmic localization of basal bodies


name: Abnormal ciliary beat pattern with reduced amplitude


name: Solid echo pattern seen on transvaginal ultrasonography


name: Retinal dystrophy, unilateral or bilateral


name: Microdontia (deciduous and permanent teeth)


name: Short toes (especially of 2nd, 3rd, and 4th toes)


name: Linear hypopigmentation on neck and limbs


name: Central indentation of upper and lower endplates


name: Irregular metaphyses (upper and lower limbs)


name: Craniofacial dysmorphism, severe (phenotypic group A)


name: Dysplastic bones, axial and appendicular (group A)


name: Vascular tortuosity, intracranial and aortic (group A)


name: Intellectual developmental delay, severe


name: Malformations of cortical development on brain imaging


name: Multiple morphologic abnormalities of the sperm flagella


name: Disorganization of axonemal and periaxonemal structures


name: Unassembled outer dense fibers at midpiece


name: Misplaced or absent central pair (9+0 pattern)


name: Global microtubule doublets disorganization


name: Thin corpus callosum seen on brain imaging


name: Multiple morphologic abnormalities of the flagella


name: Absent central pair complex (9+0 pattern) at principal piece


name: Impaired intellectual development (group B)


name: Fatty infiltration of the pancreas on imaging


name: Maturational arrest of the granulocytic neutrophil line


name: Promyelocytes and myeloblasts contain abnormal cytoplasmic vacuoles


name: Myelocytes contain enlarged ER and autophagosomes


name: Macular posterior staphyloma seen on OCT


name: Birth length less than 48 cm (range 40-48cm)


name: Delayed myelination Thickened corpus callosum


name: Normal to high thyroid-stimulating hormone (TSH)


name: Global developmental delay, mild to severe


name: vehicle cream base no.241 TRANSDERM CREAM (GRAM)


name: BUDESONIDE 1 g in 1 g NOT APPLICABLE POWDER


name: Diclofenac Sodium;Menthol 1.5%; 8% Topical application Kit [Diclovix M]


name: HOMOSALATE 9.8 g in 100 mL / OCTISALATE 4.9 g in 100 mL / OCTOCRYLENE 9.5 g in 100 mL / AVOBENZONE 2.8 g in 100 mL TOPICAL SPRAY [PLAY Antioxidant Body Mist SPF 50 With Vitamin C]


name: AVOBENZONE 1.75 g in 100 mL / HOMOSALATE 2.5 g in 100 mL / OCTISALATE 1.5 g in 100 mL / OCTOCRYLENE 3.75 g in 100 mL TOPICAL LOTION [COOLA Classic Body Sunscreen Pina Colada SPF 30]


name: AVOBENZONE 1.75 g in 100 mL / HOMOSALATE 5.0 g in 100 mL / OCTISALATE 2.0 g in 100 mL / OCTOCRYLENE 5.0 g in 100 mL TOPICAL LOTION [COOLA Classic Body Sunscreen Fragrance-Free SPF 50]


name: ZINC OXIDE 14.4 g in 100 mL TOPICAL CREAM [Bright-eyed 100% mineral Eye Cream Broad Spectrum Sunscreen SPF 40]


name: ZINC OXIDE 105 ug in 1 g TOPICAL STICK [Thinksport Sunscreen SPF 18]


name: CATHETER,INTERMITTENT 14FR FEMALE CURE #CQT14


name: CATHETER,EXTERNAL MED ROCHESTER #35102/35302


name: FOLEY ANCHORING DEVICE,CENTURION #EEFCS300XT


name: CATHETER,INTERMITTENT,MAGIC3 16FR ROCHESTER #53616G


name: EXTENSION TUBING SMITHS MEDICAL #MX451FL


name: XYLAZINE HYDROCHLORIDE 1 kg in 1 kg NOT APPLICABLE POWDER


name: AVOBENZONE 1.75 g in 100 mL / HOMOSALATE 2.5 g in 100 mL / OCTISALATE 1.5 g in 100 mL / OCTOCRYLENE 3.75 g in 100 mL TOPICAL LOTION [COOLA CLASSIC FACE SUNSCREEN Cucumber Broad Spectrum SPF 30]


name: AVOBENZONE 1.75 g in 100 mL / HOMOSALATE 5.0 g in 100 mL / OCTISALATE 2.0 g in 100 mL / OCTOCRYLENE 5.0 g in 100 mL TOPICAL LOTION [COOLA CLASSIC BODY SUNSCREEN Guava Mango Broad Spectrum SPF 50]


name: AVOBENZONE 30 mg in 1 mL / HOMOSALATE 50 mg in 1 mL / OCTISALATE 50 mg in 1 mL TOPICAL CREAM [SUPERDEFENSE BROAD SPECTRUM SPF 25 FATIGUE PLUS 1ST SIGNS OF AGE MULTI-CORRECTING VERY DRY TO DRY COMBINATION]


name: {28 (tolvaptan 15 MG Oral Tablet) / 28 (tolvaptan 30 MG Oral Tablet) } Pack


name: {56 (tolvaptan 15 MG Oral Tablet) } Pack


name: SUCRALFATE 1 kg in 1 kg NOT APPLICABLE POWDER


name: AVOBENZONE 1.75 g in 100 mL / HOMOSALATE 5.0 g in 100 mL / OCTISALATE 2.0 g in 100 mL / OCTOCRYLENE 5.0 g in 100 mL TOPICAL LOTION [COOLA CLASSIC FACE SUNSCREEN White Tea Broad Spectrum SPF 50]


name: AVOBENZONE 3 g in 100 mL / OCTISALATE 5 g in 100 mL / OCTOCRYLENE 10 g in 100 mL TOPICAL CREAM [Glow Screen SPF 40]


name: ZINC OXIDE 190 g in 1000 g / TITANIUM DIOXIDE 40 g in 1000 g TOPICAL CREAM [EltaMD UV Active]


name: Formula, Infant Oral Powder for Suspension [Gerber Good Start SoothePro]


name: MIRTAZAPINE HEMIHYDRATE 1 kg in 1 kg NOT APPLICABLE POWDER


name: HOMOSALATE 100 g in 1000 g / OCTISALATE 50 g in 1000 g / OCTOCRYLENE 60 g in 1000 g / ZINC OXIDE 90 g in 1000 g TOPICAL CREAM [Image Skincare Prevention Plus Daily Ultimate Protection]


name: HOMOSALATE 110 g in 1000 g / OCTISALATE 50 g in 1000 g / OCTOCRYLENE 60 g in 1000 g / ZINC OXIDE 90 g in 1000 g TOPICAL CREAM [Image Prevention Plus Professional Ultimate Protection Moisturizer SPF50]


name: Ointment, Multi Ingredient Topical application Ointment [Vanicream]


name: CLOPIDOGREL BISULFATE 1 g in 1 g NOT APPLICABLE POWDER


name: HOMOSALATE 120 mg in 1 mL / OCTOCRYLENE 70 mg in 1 mL / OCTISALATE 50 mg in 1 mL / AVOBENZONE 30 mg in 1 mL / DROMETRIZOLE TRISILOXANE 5 mg in 1 mL TOPICAL LOTION [Garnier Ombrelle Complete Sensitive Advanced Lightweight hypoallergenic SPF 45 Mexoryl Technology]


name: Bacitracin Zinc/Neomycin/Polymyxin B Sulfate;Benzalkonium Chloride 400 U/1 GM-3.5 MG/1 GM-5000 U/1 GM; 0.1% Multiple Routes Kit


name: Bacitracin Zinc/Neomycin/Polymyxin B Sulfate;Benzalkonium Chloride 400 U/1 GM-3.5 MG/1 GM-5000 U/1 GM; 0.1% Multiple Routes Kit [Leader All-Purpose First Aid Kit]


name: Benzalkonium Chloride;Benzalkonium Chloride 0.1%; 0.13% Multiple Routes Kit


name: Benzalkonium Chloride;Benzalkonium Chloride 0.1%; 0.13% Multiple Routes Kit [Travel First Aid Kit]


name: LIDOCAINE 5 g in 100 g TOPICAL GEL [LUBRICAINE 5]


name: LIDOCAINE 4 g in 100 g TOPICAL GEL [LUBRICAINE]


name: petrolatum 0.499 MG/MG Topical Ointment [PeriGuard Ointment]


name: ALUMINUM ZIRCONIUM TETRACHLOROHYDREX GLY 15 g in 100 g TOPICAL STICK [Secret Cocoa Butter Invisible]


name: OCTINOXATE 1.69 g in 30 mL / TITANIUM DIOXIDE 0.345 g in 30 mL TOPICAL EMULSION [SHISEIDO SYNCHRO SKIN SELF-REFRESHING FOUNDATION 430 CEDAR]


name: Lactobacillus Reuteri 100 MILLION CFU/1 PACKET Oral Powder


name: Lactobacillus Reuteri 100 MILLION CFU/1 PACKET Oral Powder [Good Start Probiotic]


name: SUSPENSION, EXTENDED RELEASE, RECON (ML)


name: Blistex Medicated Lip Balm Variety Pack (Blistex Medicated Berry Lip Balm, Blistex Medicated Lip Balm, Blistex Medicated Lip) KIT


name: Blistex Medicated Lip Balm Variety Pack (Blistex Medicated Berry Lip Balm, Blistex Medicated Lip Balm, Blistex Medicated Mint Lip Balm) KIT


name: Leader One Daily Women's Multivitamin Tablet


name: TechLITE 1/2ML 31G 15/64 inch Short Needle Insulin Syringe


name: TechLITE 3/10ML 31G 15/64 inch Short Needle Insulin Syringe


name: Pure Comfort Pressure Activated Safety Lancet 30G


name: Kroger HealthPro Twist Lancet 26G (Green)


name: Kroger HealthPro Twist Lancet 30G (Blue)


name: Kroger HealthPro Twist Lancet 33G (Yellow)


name: PURAMINO Jr DHA Powder for Suspension (Vanilla)


name: AVOBENZONE 30 mg in 1 mL / HOMOSALATE 100 mg in 1 mL / OCTISALATE 50 mg in 1 mL / OCTOCRYLENE 100 mg in 1 mL TOPICAL LOTION [SEVEN MINERALS Skin Friendly SPF 50]


name: AVOBENZONE 30 mg in 1 mL / OCTISALATE 50 mg in 1 mL / OCTOCRYLENE 50 mg in 1 mL TOPICAL LOTION [SEVEN MINERALS Skin Friendly SPF 30]


name: nutritional therapy for impaired digestive function 8 gram-240 kcal/50 gram ORAL POWDER (GRAM)


name: sodium chloride/potassium chloride/sodium citrate/rice syrup 230 mg-85 mg-120 kcal/31 gram ORAL POWDER IN PACKET (EA)


name: sodium chloride/potassium chloride/sodium citrate/rice/whey 400 mg-160 mg-150 kcal/42 gram ORAL POWDER IN PACKET (EA)


name: cardioplegic solution no.32 (maintenance 8:1)


name: OCTINOXATE 6 g in 100 mL / ZINC OXIDE 3 g in 100 mL TOPICAL LOTION [TRADER JOES ENRICH MOISTURIZING FACE BROAD SPECTRUM SPF 15]


name: OCTISALATE 50 mg in 1 g / OCTOCRYLENE 50 mg in 1 g / AVOBENZONE 30 mg in 1 g / HOMOSALATE 100 mg in 1 g TOPICAL STICK [Fruit of the Earth Sun Town City]


name: Octinoxate 3.50 g in 50 mL / Homosalate 1.50 g in 50 mL / Octisalate 1.50 g in 50 mL / Titanium Dioxide 0.74 g in 50 mL TOPICAL CREAM [PAPA RECIPE BOMBEE MOIST SUN ESSENCE]


name: Niacinamide 0.18 g in 6 mL TOPICAL LIQUID [CellExosome HE HR]


name: Niacinamide 0.09 g in 3 mL TOPICAL LIQUID [CellExosome SB]


name: Niacinamide 0.06 g in 3 mL TOPICAL LIQUID [CellExosome HR]


name: Adenosine 0.001 g in 3 mL TOPICAL LIQUID [CellExosome ST]


name: Adenosine 0.002 g in 6 mL TOPICAL LIQUID [CellExosome HE SR]


name: MYCOPHENOLATE MOFETIL 1 g in 1 g NOT APPLICABLE POWDER


name: AVOBENZONE 3 g in 100 mL / HOMOSALATE 8 g in 100 mL / OCTOCRYLENE 4 g in 100 mL / OCTISALATE 5 g in 100 mL TOPICAL CREAM [Unseen Sunscreen Broad Spectrum SPF 40]


name: AVOBENZONE 30 mg in 1 g / HOMOSALATE 100 mg in 1 g / OCTISALATE 50 mg in 1 g / OCTOCRYLENE 40 mg in 1 g TOPICAL AEROSOL, SPRAY [Tenacious Ergodyne]


name: TITANIUM DIOXIDE 89.6 mg in 1 mL / ZINC OXIDE 112 mg in 1 mL TOPICAL LOTION [Blue Lizard Baby SPF 50 Sunscreen]


name: Titanium Dioxide 74.7 mg in 1 mL / Zinc Oxide 47.5 mg in 1 mL TOPICAL LIQUID [foundcealer multi-tasking foundation Broad Spectrum SPF 20 Sunscreen 14S fair sand]


name: {2 (peanut (Arachis hypogaea) allergen-dnfp 0.5 MG Oral Powder) / 11 (peanut (Arachis hypogaea) allergen-dnfp 1 MG Oral Powder) } Pack


name: {2 (peanut (Arachis hypogaea) allergen-dnfp 0.5 MG Oral Powder [Palforzia]) / 11 (peanut (Arachis hypogaea) allergen-dnfp 1 MG Oral Powder [Palforzia]) } Pack [Palforzia Initial Dose Escalation]


name: {2 (peanut (Arachis hypogaea) allergen-dnfp 20 MG Oral Powder) } Pack


name: {2 (peanut (Arachis hypogaea) allergen-dnfp 20 MG Oral Powder [Palforzia]) } Pack [Palforzia 40 MG (Level 5)]


name: {3 (peanut (Arachis hypogaea) allergen-dnfp 1 MG Oral Powder) } Pack


name: {3 (peanut (Arachis hypogaea) allergen-dnfp 1 MG Oral Powder [Palforzia]) } Pack [Palforzia 3 MG (Level 1)]


name: {6 (peanut (Arachis hypogaea) allergen-dnfp 1 MG Oral Powder) } Pack


name: {6 (peanut (Arachis hypogaea) allergen-dnfp 1 MG Oral Powder [Palforzia]) } Pack [Palforzia 6 MG (Level 2)]


name: {2 (peanut (Arachis hypogaea) allergen-dnfp 1 MG Oral Powder) / 1 (peanut (Arachis hypogaea) allergen-dnfp 10 MG Oral Powder) } Pack


name: {2 (peanut (Arachis hypogaea) allergen-dnfp 1 MG Oral Powder [Palforzia]) / 1 (peanut (Arachis hypogaea) allergen-dnfp 10 MG Oral Powder [Palforzia]) } Pack [Palforzia 12 MG (Level 3)]


name: {1 (peanut (Arachis hypogaea) allergen-dnfp 20 MG Oral Powder) } Pack


name: {1 (peanut (Arachis hypogaea) allergen-dnfp 20 MG Oral Powder [Palforzia]) } Pack [Palforzia 20 MG (Level 4)]


name: {4 (peanut (Arachis hypogaea) allergen-dnfp 20 MG Oral Powder) } Pack


name: {4 (peanut (Arachis hypogaea) allergen-dnfp 20 MG Oral Powder [Palforzia]) } Pack [Palforzia 80 MG (Level 6)]


name: {1 (peanut (Arachis hypogaea) allergen-dnfp 100 MG Oral Powder) / 1 (peanut (Arachis hypogaea) allergen-dnfp 20 MG Oral Powder) } Pack


name: {1 (peanut (Arachis hypogaea) allergen-dnfp 100 MG Oral Powder [Palforzia]) / 1 (peanut (Arachis hypogaea) allergen-dnfp 20 MG Oral Powder [Palforzia]) } Pack [Palforzia 120 MG (Level 7)]


name: {1 (peanut (Arachis hypogaea) allergen-dnfp 100 MG Oral Powder) / 3 (peanut (Arachis hypogaea) allergen-dnfp 20 MG Oral Powder) } Pack


name: {1 (peanut (Arachis hypogaea) allergen-dnfp 100 MG Oral Powder [Palforzia]) / 3 (peanut (Arachis hypogaea) allergen-dnfp 20 MG Oral Powder [Palforzia]) } Pack [Palforzia 160 MG (Level 8)]


name: {2 (peanut (Arachis hypogaea) allergen-dnfp 100 MG Oral Powder) } Pack


name: {2 (peanut (Arachis hypogaea) allergen-dnfp 100 MG Oral Powder [Palforzia]) } Pack [Palforzia 200 MG (Level 9)]


name: {2 (peanut (Arachis hypogaea) allergen-dnfp 100 MG Oral Powder) / 2 (peanut (Arachis hypogaea) allergen-dnfp 20 MG Oral Powder) } Pack


name: {2 (peanut (Arachis hypogaea) allergen-dnfp 100 MG Oral Powder [Palforzia]) / 2 (peanut (Arachis hypogaea) allergen-dnfp 20 MG Oral Powder [Palforzia]) } Pack [Palforzia 240 MG (Level 10)]


name: {1 (peanut (Arachis hypogaea) allergen-dnfp 300 MG Oral Powder) } Pack


name: {1 (peanut (Arachis hypogaea) allergen-dnfp 300 MG Oral Powder [Palforzia]) } Pack [Palforzia 300 MG (Level 11)]


name: HOMOSALATE 107 mg in 1 mL / OCTOCRYLENE 60 mg in 1 mL / OXYBENZONE 39 mg in 1 mL / OCTISALATE 32 mg in 1 mL / AVOBENZONE 30 mg in 1 mL / DROMETRIZOLE TRISILOXANE 5 mg in 1 mL TOPICAL LOTION [Garnier Ombrelle Kids Wet N Protect Hypoallergenic SPF 45 Mexoryl Technology]


name: HOMOSALATE 150 mg in 1 mL / OCTOCRYLENE 70 mg in 1 mL / OCTISALATE 50 mg in 1 mL / AVOBENZONE 30 mg in 1 mL / DROMETRIZOLE TRISILOXANE 5 mg in 1 mL TOPICAL LOTION [Garnier Ombrelle Face Anti-Shine SPF 60 Mexoryl Technology]


name: Orbifloxacin 1 kg in 1 kg NOT APPLICABLE POWDER


name: AVOBENZONE 30 mg in 1 mL / OCTISALATE 50 mg in 1 mL / OCTOCRYLENE 70 mg in 1 mL TOPICAL LOTION [LOREAL PARIS REVITALIFT ANTI WRINKLE FIRMING MOISTURIZER SPF 25]


name: Chemokine Receptor Type 4 Interaction [EPC]


name: Orthopoxvirus VP37 Envelope Wrapping Protein Inhibitor


name: SARS coronavirus 2 RNA panel:-:Pt:Respiratory System Specimen:-:Probe.amp.tar


name: SARS coronavirus 2 RdRp gene:PrThr:Pt:Respiratory System Specimen:Ord:Probe.amp.tar


name: SARS coronavirus 2 N gene:PrThr:Pt:Respiratory System Specimen:Ord:Probe.amp.tar


name: Respiratory viral pathogens DNA & RNA panel:-:Pt:Respiratory System Specimen:Ord:Probe.amp.tar


name: SARS coronavirus 2 RNA:PrThr:Pt:Respiratory System Specimen:Ord:Probe.amp.tar


name: Middle east respiratory syndrome coronavirus RNA:PrThr:Pt:Respiratory System Specimen:Ord:Probe.amp.tar


name: SARS coronavirus 2 Ab.IgG:ACnc:Pt:Ser/Plas:Qn:IA


name: SARS coronavirus 2 Ab.IgM:ACnc:Pt:Ser/Plas:Qn:IA


name: SARS coronavirus 2 Ab.IgM:PrThr:Pt:Ser/Plas:Ord:IA


name: SARS coronavirus 2 Ab.IgG:PrThr:Pt:Ser/Plas:Ord:IA


name: SARS coronavirus 2 N gene:ThreshNum:Pt:XXX:Qn:Probe.amp.tar


name: SARS coronavirus 2 ORF1ab region:ThreshNum:Pt:XXX:Qn:Probe.amp.tar


name: SARS coronavirus 2 RNA panel:-:Pt:XXX:-:Probe.amp.tar


name: SARS coronavirus 2 N gene:PrThr:Pt:XXX:Ord:Probe.amp.tar.CDC primer-probe set N1


name: SARS coronavirus 2 N gene:PrThr:Pt:XXX:Ord:Probe.amp.tar.CDC primer-probe set N2


name: SARS coronavirus 2 RNA:PrThr:Pt:XXX:Ord:Probe.amp.tar


name: SARS coronavirus 2 N gene:ThreshNum:Pt:XXX:Qn:Probe.amp.tar.CDC primer-probe set N2


name: SARS-related coronavirus N gene:PrThr:Pt:XXX:Ord:Probe.amp.tar.CDC primer-probe set N3


name: SARS coronavirus 2 N gene:ThreshNum:Pt:XXX:Qn:Probe.amp.tar.CDC primer-probe set N1


name: SARS-related coronavirus N gene:ThreshNum:Pt:XXX:Qn:Probe.amp.tar.CDC primer-probe set N3


name: SARS coronavirus 2 RdRp gene:PrThr:Pt:XXX:Ord:Probe.amp.tar


name: SARS coronavirus 2 N gene:PrThr:Pt:XXX:Ord:Probe.amp.tar


name: AXL Receptor Tyrosine Kinase Measurement


name: Girdlestone resection arthroplasty of hip


name: Excision of diverticulum from large intestine


name: Excision of entire colon, entire rectum and entire anal canal (procedure)


name: Chemokine (C-X-C Motif) Ligand 12 Measurement


name: Does Not Interfere with Enjoyment of Life


name: Insulin-Like Growth Factor Binding Protein 7 Measurement


name: Organ or tissue replaced by other means, heart assist device


name: {21 (ethinyl estradiol 0.02 MG / levonorgestrel 0.1 MG Oral Tablet) } Pack [Alesse 21 Day]


name: {3 (5000 MG) (miconazole nitrate 40 MG/ML Vaginal Cream) } Pack


name: Transforming Growth Factor Beta 3 Measurement


name: ferric subsulfate 20 to 22 gram/100 mL MISCELL SOLUTION, NON-ORAL


name: Intervention for Congenital Heart Disease


name: Decreased glucosephosphate isomerase level


name: 2-5-Oligoadenylate Synthase 1 Measurement


name: Chemokine (C-C Motif) Ligand 13 Measurement


name: Vaccine product containing only inactivated whole Japanese encephalitis virus antigen (medicinal product)


name: Chemokine (C-X-C Motif) Ligand 7 Measurement


name: Fas Cell Surface Death Receptor Measurement


name: varicella vaccination (active) administration


name: PQ/CMC Manufacturing Site Unique Identifier Type Terminology


name: INC-MedDRA Neonatal Adverse Events Terminology


name: CDISC Protocol Study Monitoring Attribute Terminology


name: CDISC SDTM Type 1 Diabetes Findings About Test Code Terminology


name: CDISC SDTM Type 1 Diabetes Findings About Test Name Terminology


name: CDISC SEND Irradiation Field Orientation/Sequence Response Terminology


name: CDISC SEND Microbiology Test Code Terminology


name: CDISC SEND Microbiology Test Name Terminology


name: CDISC Questionnaire ADSD Version 1.0 Test Name Terminology


name: CDISC Questionnaire ADSD Version 1.0 Test Code Terminology


name: CDISC Questionnaire ANSD Version 1.0 Test Name Terminology


name: CDISC Questionnaire ANSD Version 1.0 Test Code Terminology


name: CDISC Questionnaire GAD-7 Version 2 Test Name Terminology


name: CDISC Questionnaire GAD-7 Version 2 Test Code Terminology


name: CDISC Questionnaire GMSS Version Type 1 Diabetes Test Name Terminology


name: CDISC Questionnaire GMSS Version Type 1 Diabetes Test Code Terminology


name: CDISC Questionnaire HCS Test Name Terminology


name: CDISC Questionnaire HCS Test Code Terminology


name: CDISC Questionnaire PARENT-DDS Test Name Terminology


name: CDISC Questionnaire PARENT-DDS Test Code Terminology


name: CDISC Questionnaire PARTNER-DDS Test Name Terminology


name: CDISC Questionnaire PARTNER-DDS Test Code Terminology


name: GMSS Version Type 1 Diabetes Questionnaire Question


name: Clinical Data Interchange Standards Consortium Controlled Terminology


name: Substance Registration System-Unique Ingredient Identifier


name: Carbohydrate to Insulin Ratio Device Setting


name: Anti-Neutrophil Cytoplasmic IgG Antibody Measurement


name: Cytidine-Uridine Monophosphate Kinase 2 Measurement


name: Dilute Russell's Viper Venom Time to Confirm Ratio Measurement


name: Epithelial Stromal Interaction 1 Measurement


name: Estimated Glomerular Filtration Rate from Creatinine and Urea Nitrogen Adjusted for Standard BSA


name: Estimated Glomerular Filtration Rate from Creatinine, Urea Nitrogen, and Albumin Adjusted for Standard BSA


name: Growth Hormone Binding Protein Measurement


name: Plasma Equivalent Glucose Distribution Measurement


name: Glutathione S-Transferase Y1 Subunit Measurement


name: 5-Hydroxyindoleacetic Acid Excretion Rate


name: Interferon Alpha-Inducible Protein 27 Measurement


name: Interferon-Induced Protein 44 Measurement


name: Interferon-Induced Protein 44-Like Measurement


name: Interferon Alpha-Inducible Protein 6 Measurement


name: Interferon-Induced 56 kDa Protein Measurement


name: Interferon-Induced 60 kDa Protein Measurement


name: Ubiquitin-Like Protein ISG15 Measurement


name: Macrophage Inflammatory Protein 1 Measurement


name: Mitochondrial M2 IgG Antibody Measurement


name: Macrophage Migration Inhibitory Factor Measurement


name: Interferon-Induced Protein p78 Measurement


name: N-acetyl-Beta-D-glucosaminidase to Creatinine Ratio Measurement


name: 2-5-Oligoadenylate Synthase 2 Measurement


name: 2-5-Oligoadenylate Synthase 3 Measurement


name: Platelet Derived Growth Factor Isoform AA Measurement


name: Translocase Inner Mitochondrial Membrane 10 Measurement


name: TPR-Ankyrin Repeat-containing Protein 1 Measurement


name: Tripartite Motif Containing Protein 21 Measurement


name: Tripartite Motif Containing Protein 38 Measurement


name: Tryptophan to Creatinine Ratio Measurement


name: Tissue Transglutaminase IgG Antibody Measurement


name: 11-Dehydro-Thromboxane B2 Excretion Rate


name: Vascular Endothelial Growth Factor C Measurement


name: Fusarium proliferatum IgE Antibody Measurement


name: Malassezia Species IgE Antibody Measurement


name: Bordetella pertussis Serotype Fimbrae 2/3 Antibody Measurement


name: Bordetella pertussis Filament Haemagglutinin Antibody Measurement


name: Bordetella pertussis Pertactin Antibody Measurement


name: Bordetella pertussis Toxin Antibody Measurement


name: Corynebacterium diphtheriae Toxoid Antibody Measurement


name: Clostridium tetani Toxin Antibody Measurement


name: Hepatitis A Virus IgG Antibody Measurement


name: Mycoplasma pneumoniae IgA Antibody Measurement


name: Immuno-Positron Emission Tomography Scan


name: Becquerel per Gram per Kilobecquerel per Kilogram


name: Becquerel per Milliliter per Kilobecquerel per Kilogram


name: Hour Times Becquerel per Gram per Kilobecquerel per Kilogram


name: Hour Times Becquerel per Milliliter per Kilobecquerel per Kilogram


name: Products of Conception Examined Indicator


name: Arithmetic Mean Fluorescence Intensity Unit


name: Geometric Mean Fluorescence Intensity Unit


name: Milliliter per Cubic Centimeter per Minute


name: Decreased Follicles and Absent Follicles


name: Proteinaceous Fluid in the Aqueous Humor


name: Lymphoblasts Less than 5 Percent of Bone Marrow Nucleated Cells


name: How Much Does Illness and/or Treatment Interfere with Health Question


name: How Much Does Illness and/or Treatment Interfere with Diet Question


name: How Much Does Illness and/or Treatment Interfere with Work Question


name: How Much Does Illness and/or Treatment Interfere with Active Recreation Question


name: How Much Does Illness and/or Treatment Interfere with Passive Recreation Question


name: How Much Does Illness and/or Treatment Interfere with Financial Situation Question


name: How Much Does Illness and/or Treatment Interfere with Relationship with Spouse Question


name: How Much Does Illness and/or Treatment Interfere with Sex Life Question


name: How Much Does Illness and/or Treatment Interfere with Family Relations Question


name: How Much Does Illness and/or Treatment Interfere with Other Social Relations Question


name: How Much Does Illness and/or Treatment Interfere with Self-Expression or Self-Improvement Question


name: How Much Does Illness and/or Treatment Interfere with Religious Expression Question


name: How Much Does Illness and/or Treatment Interfere with Community and Civic Involvement Question


name: Afraid Won't be Able to Have (More) Children Question


name: Worried About Passing on Genetic Risk for Cancer to Children Question


name: Worry About Telling Spouse or Partner May be Unable to Have Children Question


name: Scared of Not Being Around to Take Care of Children Someday Question


name: Can Accept if I am Unable to Have (More) Children Question


name: Overwhelmed by Thought of Trying to get Pregnant Question


name: Concerned that Spouse or Partner Will be Disappointed if Can't Get Pregnant Question


name: Worried About Ability to Get Pregnant Question


name: Worried About How Family History Might Affect Children's Health Question


name: Will Be Happy with Life Whether or Not I Have (More) Children Someday Question


name: Having (More) Children Will Make me More Nervous About Getting Cancer Again Question


name: Worry that Getting Pregnant Would Take Too Much Time and Effort Question


name: Am Cautious About Having (More) Children Because Might Not be Around to Raise Them Question


name: Stressful to Think About Trying to Get Pregnant Question


name: Will Feel Content if do Not Have (More) Children Question


name: Thought of Telling Spouse or Partner that I May be Unable to Have Children Makes me Uncomfortable Question


name: Concerned May Not be Able to Have (More) Children Question


name: Afraid Children Would Have High Chance of Getting Cancer Question


name: Asthma Daytime Symptom Diary V1.0 Questionnaire


name: Asthma Nighttime Symptom Diary V1.0 Questionnaire


name: Generalized Anxiety Disorder - 7 Version 2 Questionnaire


name: The Glucose Monitoring Satisfaction Survey Version: Type 1 Diabetes Questionnaire


name: Hypoglycemic Confidence Scale Questionnaire


name: Diabetes Distress Scale for Parents of Teens with Type 1 Diabetes Questionnaire


name: Diabetes Distress Scale for Partners of Adults with Type 1 Diabetes Questionnaire


name: ADSD Version 1.0 - Rate Breathing at Its Worst


name: ADSD Version 1.0 - Rate Wheezing at Its Worst


name: ADSD Version 1.0 - Rate Shortness of Breath at Worst


name: ADSD Version 1.0 - Rate Chest Tightness at Its Worst


name: ADSD Version 1.0 - Rate Chest Pain at Its Worst


name: ADSD Version 1.0 - Rate Cough at Its Worst


name: ANSD Version 1.0 - Rate Breathing at Its Worst


name: ANSD Version 1.0 - Rate Wheezing at Its Worst


name: ANSD Version 1.0 - Rate Shortness of Breath at Worst


name: ANSD Version 1.0 - Rate Chest Tightness at Its Worst


name: ANSD Version 1.0 - Rate Chest Pain at Its Worst


name: ANSD Version 1.0 - Rate Cough at Its Worst


name: GAD-7 Version 2 - Feeling Nervous Anxious or On Edge


name: GAD-7 Version 2 - Not Able to Stop or Control Worrying


name: GAD-7 Version 2 - Worrying Too Much About Things


name: GAD-7 Version 2 - Being Restless Hard to Sit Still


name: GAD-7 Version 2 - Becoming Easily Annoyed or Irritable


name: GAD-7 Version 2 - Feel Afraid If Something Awful Happen


name: GMSS Version Type 1 Diabetes - More Satisfied With My Diabetes


name: GMSS Version Type 1 Diabetes - Think About Diabetes More


name: GMSS Version Type 1 Diabetes - Takes Too Much Time to Use


name: GMSS Version Type 1 Diabetes - Doesn't Seem as Accurate


name: GMSS Version Type 1 Diabetes - Makes Me Worry a Lot


name: GMSS Version Type 1 Diabetes - Is Too Much of a Hassle to Use


name: GMSS Version Type 1 Diabetes - Gives Me Numbers I Don't Trust


name: GMSS Version Type 1 Diabetes - Feel Less Restricted by Diabetes


name: GMSS Version Type 1 Diabetes - More Frustrated With My Diabetes


name: GMSS Version Type 1 Diabetes - Be More Spontaneous in My Life


name: GMSS Version Type 1 Diabetes - Too Many Skin Irritations/Bruises


name: GMSS Version Type 1 Diabetes - Gives Me Results Don't Make Sense


name: GMSS Version Type 1 Diabetes - Feel More Down and Depressed


name: GMSS Version Type 1 Diabetes - More Open to New Experiences


name: GMSS Version Type 1 Diabetes - Is Too Painful to Use


name: GMSS Version Type 1 Diabetes - Subscale: Openness


name: GMSS Version Type 1 Diabetes - Subscale: Emotional Burden


name: GMSS Version Type 1 Diabetes - Subscale: Behavioral Burden


name: GMSS Version Type 1 Diabetes - Subscale: Trust


name: GMSS Version Type 1 Diabetes - Total Scale


name: PARENT-DDS - Unappreciated for Ways I Help


name: PARENT-DDS - Trust Teen Take Care of Diabetes


name: PARENT-DDS - Low Blood Sugars Away From Home


name: PARENT-DDS - Teen Ignore or Forget Diabetes


name: PARENT-DDS - Taking Too Much of My Energy


name: PARENT-DDS - Low Blood Sugars When Sleeping


name: PARENT-DDS - No One Notices Diabetes Hard on Me


name: PARENT-DDS - Doesn't Do Enough Manage Diabetes


name: PARENT-DDS - Teen Doesn't Have Right Doctor


name: PARENT-DDS - Blame Me If Not Well-controlled


name: PARENT-DDS - Leave Home and Cannot Protect Him


name: PARENT-DDS - Teen Ignores My Suggestions


name: PARENT-DDS - Doesn't Get Expert Medical Help


name: PARENT-DDS - Motivate Teen Take Care Diabetes


name: PARENT-DDS - Teen Not Prepared Once Adult


name: PARENT-DDS - Only One Takes Responsibility


name: PARENT-DDS - My Nagging Hurting Relationship


name: PARENT-DDS - Personal Distress: Moderate


name: PARENT-DDS - Teen Management Distress: Sum


name: PARENT-DDS - Teen Management Distress: Mean


name: PARENT-DDS - Teen Management Distress: Moderate


name: PARENT-DDS - Parent/Teen Relationship Distress: Sum


name: PARENT-DDS - Parent/Teen Relationship Distress: Mean


name: PARENT-DDS - Parent/Teen Relationship Distress: Moderate


name: PARENT-DDS - Healthcare Team Distress: Sum


name: PARENT-DDS - Healthcare Team Distress: Mean


name: PARENT-DDS - Healthcare Team Distress: Moderate


name: PARTNER-DDS - Worry About Low Blood Sugars


name: PARTNER-DDS - How Involved Managing Diabetes


name: PARTNER-DDS - Partner Doesn't Try Hard Enough


name: PARTNER-DDS - Overwhelmed by Constant Demands


name: PARTNER-DDS - How to Best Help Partner Manage


name: PARTNER-DDS - Silent About My Partner's Diabetes


name: PARTNER-DDS - Taking Too Much of My Energy


name: PARTNER-DDS - No One Notices Diabetes Hard On Me


name: PARTNER-DDS - More I Try The Worse Things Get


name: PARTNER-DDS - Guilty Not Doing Enough to Help


name: PARTNER-DDS - Can't Get Partner Improve Attitude


name: PARTNER-DDS - Failing to Help Partner Manage


name: PARTNER-DDS - Help My Partner Always a Battle


name: PARTNER-DDS - Partner Ignores My Suggestions


name: PARTNER-DDS - Diabetes Often Interrupts Plans